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ABSTRACT 
 
DANIEL I. DOMINGUEZ: Transcriptome Dynamics during the Mammalian Cell Cycle. 
(Under the Direction of Zefeng Wang, Ph.D.) 
 
In recent years, technologies capable of simultaneously deciphering the nucleotide 
sequence and expression level of most RNAs in the cell have challenged the simplistic 
view of one gene-one protein. It is now well-appreciated that the cell has a tremendous 
level of flexibility during RNA processing (i.e. alternative splicing) to produce multiple 
coding mRNAs from single gene unit. Another surprising find is that most of the genome 
is transcribed, which leads to the production of a large proportion of RNAs without coding 
potential (i.e. lncRNAs). Global transcriptome rearrangements have been shown to occur 
during and regulate key biological processes like development and differentiation.  
This work focuses on bettering our current understanding of the mammalian cell 
cycle in the context of transcriptome-wide dynamics.  Progression through the mitotic cell 
cycle has been shown to require periodic gene function. Conventionally, these biological 
oscillations are thought to be primarily mediated by transcription and protein degradation.  
Here we report sequencing of the human transcriptome through two continuous cell 
cycles, revealing periodic dynamics of over 1,000 coding and non-coding RNAs. 
Additionally, we uncovered widespread periodic splicing events, many of which affect 
genes that regulate cell cycle. Mechanistically, we show that Cdc2-like kinase 1 
undergoes periodic fluctuations through an auto-inhibitory circuit to control a network of 
iv 
periodic splicing events that are required for cell cycle. Our findings elucidate a novel 
mechanism for periodic gene regulation independent of transcription, suggesting that 
proteome expansion via splicing adds a new regulatory layer for control of gene function 
during cell division. 
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I. Introduction 
 
The mitotic cell cycle   
The cell division cycle is an indispensable biological process that affords living 
organisms the ability to replicate, divide and evolve. Across eukaryotes, there are 
differences in cell division but the general set of factors and order of events in cell cycle 
control are conserved (Norbury and Nurse 1992).  Here I provide an overview of our 
current understanding of the mitotic cell cycle and raise some of the central questions 
pertinent to the research presented below.   
Actively dividing cells make orderly transitions through the following cell cycle 
stages (Norbury and Nurse 1992). Gap 1 phase (G1) is generally considered a resting 
state where cells await a signal to enter a new cell cycle. If a signal is received, cells 
prepare the molecular machinery that will be required for duplicating the genome in S 
phase. Upon accurate completion of DNA synthesis, cells enter another a second gap 
phase (G2). In G2 the molecular machinery required for mitosis (M) and the separation 
of daughter cells (cytokinesis) is synthesized. Mitosis is divided further into stages largely 
based on the status of sister chromatids. At the onset of mitosis the nuclear envelope is 
broken down, DNA begins to condense and spindle poles form at opposite ends of the 
cell (prophase). Following complete DNA condensation, a part of the chromosome known 
as the centromere forms attachments with microtubules that emanate from the spindle 
poles.  A proteinacious structure known as the kinetochore bridges centromeric DNA and 
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spindle microtubules. These attachments are made at the center plane of the cell known 
as the metaphase plate. Once all chromosomes are aligned at the metaphase plate, sister 
chromatids are pulled away from each other towards opposite ends of the cell during 
anaphase and telophase. If the genetic material has been distributed equally without 
errors, cells undergo cytokinesis and separate into two daughter cells. The fidelity of 
molecular events that occur, especially during genome duplication and chromosome 
segregation, is tightly regulated and frequently altered in disease (as discussed below).  
 
Regulation of cell cycle progression 
Cell cycle regulation is largely achieved through waves of periodic gene function 
that are under the control of a small family of protein kinases known as the cyclin-
dependent kinases (CDKs). CDKs are the master regulators that orchestrate cell cycle 
transitions (Morgan 1997; Satyanarayana and Kaldis 2009). In humans, there are four 
major CDKs (CDK1, CDK2, CDK4 and CDK6) with well-defined roles in cell cycle control 
(Malumbres and Barbacid 2009). CDK activity requires the binding of regulatory cyclin 
subunits of which there are four different classes (A-, B-, D-, and E- type) (Malumbres 
and Barbacid 2005). The synthesis, ability complex with CDKs and the destruction of 
regulatory cyclin subunits is a function of cell cycle stage. Therefore, CDK activity is also 
a function of cell cycle stage.  
Cell cycle control by CDK-cyclin holoenzymes has been extensively reviewed 
(Morgan 1997; Malumbres and Barbacid 2009; Satyanarayana and Kaldis 2009; 
Malumbres 2011). Briefly, it involves sequential oscillations of D-, E-, A-, and B- type 
cyclins during G1, early S, late S and G2/M, respectively. The D-type cyclins are 
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synthesized in G1 phase after cells sense pro-mitogenic signaling cues which are typically 
received in the form of growth factors that stimulate proliferative signaling pathways (i.e. 
Ras/Raf/Erk) (Malumbres and Barbacid 2001). Stimulation of these pathways induces the 
transcription of Cyclin D molecules while simultaneously blocking their protein turnover 
(Diehl, Cheng et al. 1998; Malumbres and Pellicer 1998). D-type cyclins complex with 
and activate CDK4 and CDK6 which promotes cell cycle entry.  Active CDK4/6-Cyclin D 
enzymes promote the expression and accumulation of E-and then A- type cyclins. CDK2-
Cyclin E activity leads to the deposition and assembly of the pre-replication machinery on 
DNA (Harbour, Luo et al. 1999) and prepares the genome for duplication. When Cyclin A 
peaks in expression, it displaces Cyclin E from CDK2 and initiates DNA synthesis while 
ensuring that DNA replication only occurs once per cell cycle (Hwang and Clurman 2005). 
Interestingly, it has been shown that Cyclin E can stimulate DNA synthesis independent 
of CDK2 (Geng, Lee et al. 2007).  Upon completion of DNA synthesis, Cyclin A changes 
CDK preference and couples with CDK1 to drive the transition from S to G2 and from G2 
to early mitosis (although the precise timing and function of Cyclin A during late G2 and 
M is still under investigation) (Woo and Poon 2003). Cyclin A is rapidly degraded as the 
nuclear envelope breaks down.  During G2 the levels of B-type cyclins accumulate and 
ultimately reach threshold that leads to complex formation with CDK1 (Solomon, Glotzer 
et al. 1990).  Cyclin B-CDK1 activity controls key events early in mitosis including nuclear 
envelope breakdown, chromosome condensation and spindle pole formation (Lindqvist, 
Rodriguez-Bravo et al. 2009).  Cyclin B molecules also serve as sensors for appropriate 
attachment of chromosomes to spindle microtubules during metaphase. If chromosomes 
are properly oriented and correctly attached to the mitotic spindles, Cyclin B is degraded, 
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this degradation promotes sister chromatid segregation (Acquaviva and Pines 2006). 
Successful chromosome segregation initiates a complex set of events involving motor 
proteins, major cytoskeletal rearrangements and DNA de-condensation factors that drive 
the separation of daughter cells.   
 
RNA dynamics during the cell cycle 
Periodic gene function can be achieved by mechanisms that control transcription, 
translation, mRNA stability, protein modification and protein stability. Importantly, these 
mechanisms synergize to fine tune gene function during cell division. Here I focus 
primarily on the production, processing and maintenance of RNAs during cell cycle. 
Periodic genes can be clustered into three major waves based on their peak expression 
at G1/S, G2/M and M/G1 (Bahler 2005). These expression waves are largely under the 
control of CDK activity.  A large body of work has focused on determining the set of 
transcripts that oscillate during cell cycle and the underlying regulatory mechanisms that 
control these gene expression behaviors. First, I review the results of large-scale data 
sets that have aimed at defining the cell cycle-dependent transcriptome, and 
subsequently I discuss the major regulatory mechanisms underlying these dynamics. 
 
The cycle-dependent gene expression program  
Early gene expression profiling studies in yeast and human cells revealed that a 
large set mRNAs fluctuate during cell cycle (Cho, Campbell et al. 1998; Spellman, 
Sherlock et al. 1998; Cho, Huang et al. 2001; Oliva, Rosebrock et al. 2005).  One of the 
first and most comprehensive studies in human cells was performed using the ovarian 
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cancer HeLa cell line (Whitfield, Sherlock et al. 2002). The authors applied various 
chemical-based synchrony techniques and tracked changes in mRNA levels using 
microarray assays. Chemical cell synchrony has advantages over serum 
starvation/stimulation because serum stimulation activates more than a cell cycle-
dependent transcriptional program and confounds the interpretation of the data (Iyer, 
Eisen et al. 1999). Furthermore, serum starvation promotes entry into G0, which is 
different from G1 phase (Coller, Sang et al. 2006).  
To identify periodic genes, the authors applied a Fourier transform method capable 
of identifying expression patterns with sinusoidal shapes. This method was sensitive 
enough to capture most of the previously known periodically expressed genes. In total, 
about 600 periodic mRNAs (if only microarray probes that correspond to current transcript 
annotations are counted) were identified. These data also demonstrated that periodic 
peak expression can occur at any point during cell cycle, however most transcripts tend 
to cluster into the three waves discussed above (G1/S, G2/M and M/G1).  An important 
feature gleaned from this work is that genes with similar functions during cell cycle have 
near-identical expression patterns. For example, the DNA-synthesis machinery is 
expressed in two waves, an early and a late phase. Early S-phase genes encode 
components of the pre-replicative machinery while the late S-phase genes include factors 
required for continued DNA synthesis and factors involved in DNA repair. Similar 
observations were made in early and late G2 phases.  
While this work was been very informative, several questions remained open. Are 
these observations general to other cell lines or tissue types? This is especially pertinent, 
given that HeLa cells lack two critical cell cycle-dependent transcriptional regulators (p53 
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and Rb) (Scheffner, Munger et al. 1991).  Subsequent genome-wide studies followed the 
Whitfield et al. (2002) study and have helped shed some light on the general features of 
the cell cycle-dependent transcriptome.  Four additional studies using normal foreskin 
fibroblast (Bar-Joseph, Siegfried et al. 2008), the U2OS osteosarcoma (Grant, Brooks et 
al. 2013), the HaCaT keratinocyte cell line (Pena-Diaz, Hegre et al. 2013) and I include 
the data that will be presented below from synchronized HeLa cells. Interestingly the 
overlap between any two studies appears to be between 40%-70% with the HaCaT cell 
line have the least overlap with any other cell lines. As it turns out, the overlap between 
the two HeLa studies performed, is not particularly greater that the overlap across 
different cell lines. These data likely reflect the inherent differences across lab lines of the 
same cell line. Cell cycle-dependent transcription programs across all cell types analyzed 
thus far share a core set of genes. However, this gene set is very small with only 97 genes 
across 4 studies and as few as 67 across 5. These 67 core genes tend to have high 
periodic scores (meaning their expression pattern is robustly sinusoidal) indicating that 
this modest overlap might be a consequence of the constraints imposed by the 
methodologies used. Our analysis of these 67 genes indicates that they are 
predominantly involved in mitotic control.  This may reflect an absolute requirement for 
oscillations in mitotic RNAs.  As one would expect there are deleterious consequences if 
condensation of the genome or breakdown of the nucleus occurs at inappropriate stages. 
 
The G1/S wave 
Are the changes in mRNA dynamics due to transcriptional regulation? If so, can 
the underlying transcription control factors or epigenetic modifiers be identified? The 
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underlying regulatory mechanisms that control cell cycle-dependent gene expression are 
best understood in the context of transcriptional regulation by the combined actions of 
repressors and activators.  
Transcriptional regulation at G1/S transition (reviewed in (Bertoli, Skotheim et al. 
2013)) begins with the Cyclin D-CDK4-mediated phosphorylation of Rb, a key 
transcriptional repressor and tumor suppressor. Rb is one of three (Rb, p107 and p130) 
major cell cycle proteins which generally function by binding and inhibiting the action of 
the E2F family of transcription factors (Johnson and Schneider-Broussard 1998; Wong, 
Dong et al. 2011).  In a resting state, Rb is bound to activator E2Fs preventing them from 
associating with the promoters of periodic genes (Dyson 1998). Phosphorylation of Rb by 
CyclinD-CDK4/6 releases the Rb-E2F interaction and thus, E2F is free to bind DNA and 
activate a widespread transcriptional program.  The vast majority of the genes that 
increase in expression during the G1/S wave contain E2F binding sites at their promoters 
(Whitfield, Sherlock et al. 2002; Grant, Brooks et al. 2013). Furthermore, genes known to 
be regulated by E2F at their promoters as measured by E2F chromatin 
immunoprecipitation experiments are highly enriched in the G1/S category (Grant, Brooks 
et al. 2013). Interestingly, the overlap between the G1/S transcriptional wave genes and 
those bound by E2F is not complete. This likely reflects the complexity of transcriptional 
regulation by numerous transcription factors (as discussed below) as well as the cell 
cycle-independent functions of E2F proteins (Engelmann and Putzer 2012).  Furthermore, 
it is unclear if other aspects of mRNA processing, independent of transcription, contribute 
to the observed change in mRNA levels in genome-wide studies. This possibility will be 
discussed in more detail below.  
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Examination of the epigenetic modifications of the G1/S cluster revealed targeting 
by polycomb repressor complex (PRC) which binds DNA via the histone H3 lysine 27 tri-
methylation mark to silence transcription (Pena-Diaz, Hegre et al. 2013).  More generally, 
histone deacetylase (HDACs) inhibitors induce G1/S arrest in various cell lines by 
increasing the transcription of CDK inhibitors (Newbold, Salmon et al. 2013). Drugs that 
target the epigenetic landscape of actively dividing cells are emerging as potent inhibitors 
of cell cycle progression. Although the details regarding the specific mechanisms remain 
unclear, these small molecules have been shown to disrupt the cell cycle-dependent 
expression programs (McLaughlin, Finn et al. 2003; Li, Li et al. 2013) 
A key feature of this transcriptional program is its ability to auto-regulate its own 
oscillations.  For example, some of the earliest genes activated in the G1/S expression 
wave serve as positive feedback regulators that strengthen the transcriptional activity of 
E2Fs (Skotheim, Di Talia et al. 2008). One such positive feedback regulator is Cyclin E 
which serves to further phosphorylate Rb proteins. This feed-forward circuit is thought to 
encode (or strengthen) the all-or-nothing response of cell cycle commitment. While the 
importance positive feedback by transcriptional control is undoubtedly important, it 
appears that cellular commitment (the all-or-nothing response) to divide precedes 
feedback transcription (Eser, Falleur-Fettig et al. 2011). Genes expressed later in the 
transcriptional wave serve to turn off the system.  These include three E2F family 
transcriptional repressors (E2F6, E2F67, and E2F8) that displace the E2F activators from 
the promoters of G1/S genes to turn off the G1/S wave (Christensen, Cloos et al. 2005; 
Moon and Dyson 2008; Westendorp, Mokry et al. 2012).  
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The G2/M wave 
Another striking feature of the G1/S wave is its ability to promote the expression of 
factors that will directly or indirectly initiate the subsequent G2/M expression wave. G2/M 
transcriptional regulation is less well defined than G1/S. A key factor involved in the G2/M 
transition is FOXM1 (although there are also roles for this transcription factor in DNA 
synthesis) (Grant, Brooks et al. 2013) (Wierstra and Alves 2007; Wierstra 2013; Wierstra 
2013). Early studies demonstrated that FOXM1 activates the expression of Cyclin B, 
Cyclin A and Cdc25B (a key cell cycle phosphatase) in G2 and M, both of which are 
required for progression through mitosis. Later it was found that the vast majority of the 
G2/M wave genes are bound by FOXM1 as measure by CHIP assays (Grant, Brooks et 
al. 2013). Grant et al., demonstrated that placing the DNA-binding motif corresponding to 
FOXM1 protein in a synthetic reporter construct led to periodic expression of the reporter, 
disrupting FOXM1 levels in these cells abrogated the periodic expression behavior of the 
reporter (Grant, Gamsby et al. 2012). Consistent with all the findings described, loss of 
FOXM1 leads to mitotic arrest, chromosome instability and inhibition of proliferation 
(Laoukili, Kooistra et al. 2005).   
 
The M/G1 wave 
The M/G1 transitions is less clearly understood. The expression of genes very 
early in G1 phase appears to be limited, as compared with other cell cycle stages 
(Fukuoka, Uehara et al. 2013). Fukuoka et al. demonstrate that about 298 genes peak in 
expression early in G1 and may be controlled by a set of putative transcription factors 
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including FOXA1, PITX2, and PAX6A. As will be shown below, the genes that belong to 
this cluster do not have major cell cycle functions. It’s also worth noting, that during mitosis 
transcription is mostly inactive which likely explains the lack of a clear G2/M expression 
wave. 
Despite our current global and mechanistic understanding of cell cycle progression 
many questions remain. Do the observed changes in mRNA correlate with a change in 
protein level? Of the periodic genes identified, how many of them are required for cell 
cycle progression? 
  
Quality control checkpoints in cell cycle  
The DNA-damage checkpoint 
 The DNA damage checkpoint senses errors during genome duplication and other 
genotoxic stresses that may be unrelated to DNA synthesis (Kastan and Bartek 2004; 
Bartek, Bartkova et al. 2007; Bartek and Lukas 2007).  Damaged DNA leads to the 
transmission of a signal to the sensing kinases, ATM and/or ATR (Reinhardt and Yaffe 
2009; Smith, Tho et al. 2010). The type of DNA damage and the cell cycle stage in which 
it occurred determines the preference for ATM or ATR signaling. ATM responds primarily 
responds to double strand breaks, while ATR deals with damage arising from exposure 
to ultraviolet light or stalled DNA replication. Upon damage, ATM and ATR rapidly 
phosphorylate and activate the CHEK1 (Patil, Pabla et al. 2013) and CHEK2 (Bartek and 
Lukas 2003; Nevanlinna and Bartek 2006) kinases, respectively.  CHEK1/2 activity 
stabilizes the tumor suppressor and transcription factor p53 by phosphorylating key 
residues that prevent p53 degradation. p53 accumulation activates the transcriptional 
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induction of CDK inhibitors, DNA repair factors and apoptotic proteins. In this way, the 
cell can arrest and repair the damage, enter a state of cellular senescence or undergo 
apoptosis. Cell fate is governed by the severity/repairability of the damage and the 
oncogenic state of the cell in question.  
 
The spindle assembly checkpoint 
 During mitosis, the spindle assembly checkpoint ensures proper attachment of 
sister chromatids to microtubules and correct chromosome alignment at the metaphase 
plate (Foley and Kapoor 2013).  The anaphase promoting complex (APC) and the mitotic 
checkpoint complex (MCC) sense defects and communicate with each other to coordinate 
mitosis. The APC is a dynamic complex that serves to specifically degrade cell cycle-
related factors, including Cyclin B (Peters 2006). Cyclin B is targeted by a specificity factor 
within the APC known as CDC20 (Glotzer, Murray et al. 1991; Hwang, Lau et al. 1998; 
Kim, Lin et al. 1998). Cyclin B loss triggers anaphase onset by mechanisms that will not 
be discussed here. The APC is only active when sister chromatids are aligned and 
appropriately attached at the metaphase plate. Regulation of the APC comes primarily 
from the status of the kinetochore. Unattached kinetochores promote the assembly of the 
MCC which sequesters CDC20 at that kinetochore (Foley and Kapoor 2013). In this way, 
unattached kinetochores inhibit APC activity via MCC-mediated sequestration of CDC20. 
If cells remain in mitosis for a prolonged period of time or segregate with errors, cells 
typically undergo apoptosis. The mechanisms that trigger apoptosis in response to these 
errors remain unclear (Foley and Kapoor 2013). It is thought that accumulation of DNA 
 
 
12 
damage from aberrant segregation involves mechanisms that activate p53 (Hayashi, 
Cesare et al. 2012); (Orth, Loewer et al. 2012).  
 
RNA processing  
Transcription, RNA splicing and alternative splicing  
In most human genes, coding sequences (exons) are interrupted by non-coding 
sequences (introns) that must be removed during or after transcription (Pan, Shai et al. 
2008; Wang, Sandberg et al. 2008). The structural determinants of a pre-mRNA are at 
the beginning of an intron or exon-intron junction known as the 5 splice site (ss) and at 
the end of the intron or intron-exon junction known the 3’ ss. Splice sites contain a short 
stretch of conserved sequence features (reviewed by (Fu 2004; Wang and Burge 2008; 
Barash, Calarco et al. 2010)). The removal of intervening introns from pre-mRNAs is 
catalyzed by the spliceosome, a large dynamic ribonucloeprotein complex containing 
hundreds of proteins and a set of small nuclear RNAs (snRNAs).  Generally, the 
spliceosome assembles on nascent pre-mRNAs through base-pairing interactions 
between the ss and snRNAs within the spliceosome. Spliceosome assembly and 
dynamics culminate in the proximity-based chemical reaction between the 5’ and 3’ splice 
sites of consecutive exons.  While the actual splicing of two exons into a contiguous RNA 
requires no ATP and is chemically simple, the assembly and dynamics of the spliceosome 
require the combined action of kinases and helicases. The precise stepwise assembly of 
the spliceosome, which is best understood in yeast, will not be discussed in detail here. 
Instead, more focus will be placed on alternative splicing (AS), a process whereby the 
cell can make a choice regarding the sequences which are retained in the final mRNA.    
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In higher eukaryotes, AS enables most single gene units to produce multiple 
coding mRNAs and therefore potently magnifies proteomic diversity. The impact of AS in 
producing a wealth of transcript diversity is exemplified by the DSCAM gene in flies. Over 
30,000 different splice variants can be produced from this single gene unit and most have 
been observed. The number of possible splice from DSCAM alone is about two times the 
total number of genes in the D. melanogaster genome (Park and Graveley 2007; Sun, 
You et al. 2013). High-throughput sequencing technologies have enabled the assessment 
of splicing patterns of most transcripts in cells. The application of these assays to dynamic 
processes has made it clear that, much like transcriptional programs, AS programs 
control biological events. These include cellular differentiation (Xue, Ouyang et al. 2013), 
development (Cooper 2005), the circadian rhythm (Hughes, Grant et al. 2012), 
oncogenesis (reviewed in (Venables 2004; Kalnina, Zayakin et al. 2005; Gardina, Clark 
et al. 2006; Skotheim and Nees 2007), the epithelial to mesenchymal transition (Shapiro, 
Cheng et al. 2011), the stem cell state (Gabut, Samavarchi-Tehrani et al. 2011; Han, 
Irimia et al. 2013) and even speciation (Su, Wang et al. 2006; Chen, Wu et al. 2011).  
Regulation of alternative splicing primarily comes from cis-sequence elements 
near ss. These short sequences of RNA (6-10 bp) typically recruit trans-acting splicing 
factors that promote or inhibit the use of adjacent splice sites (Wang and Burge 2008).   
 
SR proteins 
The serine/arginine-rich (SR) proteins are a major class of trans-acting splicing 
factors that control AS. The SR protein family consists of nine highly conserved members 
(SFRS1-7, 9 and 11). These factors are characterized by an RNA recognition motif (RRM) 
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that specifically recognizes RNA and a functional arginine-serine (RS) repeat module that 
alters splicing outcomes. The modes by which splicing regulation occurs once a trans-
factor occupies a cis-RNA element are diverse and still being actively investigated. It is 
generally accepted that trans factors alter early to intermediate assembly steps of the 
spliceosome at nearby exons to promote or inhibit the use of adjacent splice sites.  
SR proteins are regulated by post-translational modifications (i.e. phosphorylation, 
acetylation and ubiquitnation) that alter their localization, stability or activity in response 
to various signaling cues. These dynamic modifications have been shown to stimulate 
rapid signal-dependent changes in AS that control phenotypic outputs such as apoptosis 
(Edmond, Moysan et al. 2011; Shi, Nishida et al. 2011).  SR protein phosphorylation has 
also been shown to depend on cell cycle stage with a general increase in canonical SR 
protein phosphorylation during mitosis (Gui, Lane et al. 1994), however the functional 
consequences of such increases or responsible kinase(s) are not known. Signaling 
pathways, including the mammalian target of rapamycin (MTOR) pathway (DD and ZW), 
the PI3kinase/Akt (Zhou, Qiu et al. 2012) pathway and oncogenic transformation by Ras 
have been shown to induce widespread changes in AS. Importantly, the mechanisms 
driving these changes appear to be via SR protein phosphorylation.  
 It is worth noting that alternative splicing regulation is very complex. In addition to 
the SR proteins discussed, hundreds of other bona fide and putative splicing regulators 
are encoded in the human genome and are frequently co-expressed in many cell types 
(as reviewed in (Wang and Burge 2008)). The location of cis- elements within pre-mRNAs 
(i.e. exonic vs. intronic) can determine whether the same sequence element will activate 
or repress splicing (Wang, Ma et al. 2012). Furthermore, splicing factors with opposing 
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functions (activators/repressors) have been shown to have a high-degree of overlapping 
RNA sequence specificity, making it difficult to predict outcomes (Wang, Xiao et al. 2013). 
Additionally, because most splicing occurs co-transcriptionally it is also affected by 
promoter choice and transcription rate (Cramer, Caceres et al. 1999; Kornblihtt 2007; 
Schor, Gomez Acuna et al. 2013) as well as local chromatin structure, nucleosome 
positioning and histone modifications (reviewed by (Luco, Allo et al. 2011). These diverse 
mechanisms of AS regulation have made it nearly impossible to decipher the so-called 
“splicing code.”  
 
Cdc2-like kinases  
CLK kinases were originally discovered due to their similarity to the cell division 
cycle 2 proteins (CDC2/CDK1) but, in contrast to CDKs, CLKs do not require the binding 
of cyclin subunits (Ben-David, Letwin et al. 1991). To date, no cell cycle-dependent 
functions for these proteins have been demonstrated. Humans encode four CLK paralogs 
(CLK1, 2, 3 and 4), of which CLK1, 2 and 4 appear to be ubiquitously expressed whereas 
CLK3 is restricted to the testes (Nayler, Stamm et al. 1997).  CLK1 and CLK4 are most 
similar to each other at the protein and gene level and are frequently considered to be 
functionally redundant (although our results demonstrate that this may not be the case). 
Early studies on CLKs demonstrated that these factors have dual-specificity for serine/ 
threonine and tyrosine residues (Ben-David, Letwin et al. 1991). Protein purification 
studies revealed extensive auto-phosphorylation at several residues, indicating that these 
factors may be constitutively active enzymes (Nayler, Schnorrer et al. 1998). In vitro 
studies demonstrated that CLKs can phosphorylate two key splicing factors, SRSF1 and 
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SRSF2 (Colwill, Feng et al. 1996; Colwill, Pawson et al. 1996; Duncan, Stojdl et al. 1998; 
Moeslein, Myers et al. 1999; Prasad and Manley 2003; Ngo, Chakrabarti et al. 2005; 
Bullock, Das et al. 2009). Using in vitro splicing assays, it was shown that hypo- or hyper- 
phosphorylation of these two factors reduces their ability to control splicing (Prasad, 
Colwill et al. 1999).  Interestingly, adding active CLK1 kinase to in vitro splicing assays 
generally inhibits splicing regulation altogether. Conversely, doping an in vitro splicing 
assay with a catalytic mutant of CLK1 enhances splicing. In cells, CLK1 has been shown 
to interact with a number of SR proteins and co-localizes with splicing factors at nuclear 
speckles (a nuclear body thought to serve as a storage compartment for splicing 
regulators) (Colwill, Pawson et al. 1996). 
A striking feature of CLK1 and 4 (hereto referred as CLK1/4) is their ability to tightly 
auto-regulate their own activity through alternative splicing (Duncan, Stojdl et al. 1997).  
The fourth exon of CLK1/4 pre-mRNAs can be excluded from the final transcript. Exon 4 
skipping results in a coding frame shift which leads to the introduction of premature stop 
codon, thus producing a truncated protein that lacks kinase activity. CLK1/4 kinase 
activity leads to the production of non-functional (exon 4 exclusion) transcripts, while loss 
of CLK1/4 activity promotes the production of functional transcripts (exon 4 inclusion). 
CLK1/4 auto-regulation occurs very rapidly, but the underlying molecular mechanisms 
remain unclear. Presumably an intermediate trans-acting splicing factor is 
phosphorylated by CLK1/4 to regulate this event, but this factor has not been identified. 
In addition to this auto-control mechanism, I have noted (DD and ZW) that CLK1/4 activity 
also regulates total CLK1/4 mRNA levels, probably by transcriptional control. Why would 
the cell evolve a multi-layer mechanism for CLK1 auto-regulation? I speculate that this 
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tight form of auto-regulation ensures the fine control of active CLK1/4 enzymes. Indeed, 
disrupting the levels of CLK1 in cells can have deleterious consequences, as will be 
demonstrated below. Furthermore, I demonstrate that CLK1/4 auto-regulation extends 
beyond the RNA level. Interestingly, CLK2 and CLK3 do not auto-regulate in this way (DD 
and ZW).  
It was recently found that partially processed CLK1/4 transcripts reside in the 
nucleus, poised to be post-transcriptionally spliced at the same region described above 
(Ninomiya, Kataoka et al. 2011). Upon heat-shock the cell quickly splices these “pre-
mRNAs” to produce functional transcripts and increases protein levels. Furthermore, the 
authors of this study demonstrated that this stress-induced splicing also increased the 
phosphorylation of CLK1 substrates. These include two SR proteins (SRSF10 and 
SRSF4).  Phenotypically, the consequence of these events remains unclear.   
CLK1 has also been shown to regulate post-transcriptional processing of other 
pre-mRNAs. In platelets, which lack a nucleus and therefore the capacity to transcribe 
RNAs, CLK1 responds to the coagulation cascade and coordinates the splicing of a pool 
of tissue factor (TF) pre-mRNAs (TF is required for the coagulation cascade) (Schwertz, 
Tolley et al. 2006). In this case, CLK1 phosphorylates a specific SR protein, SRSF1. 
Although details regarding how CLK1 stimulates the activity of the spliceosome via 
SRSF1 phosphorylation are unclear, this form of splicing regulation is very interesting.  
This highly-specialized mechanism of splicing regulation affords platelets control over 
gene expression even in the absence of a nucleus.    
Signal-dependent post-transcriptional splicing, which could be considered a 
delayed form of AS, is emerging as an important mode of gene regulation. Post-
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transcriptional splicing bypasses the necessity for transcription, allowing the cell to adapt 
to the environment very quickly. I hypothesize that post-transcriptional splicing is a form 
of gene regulation which is far more prevalent than currently appreciated. The application 
of high-throughput techniques to resolve time-dependent transcriptome dynamics will be 
instrumental in uncovering these events.  
 
Cellular regulation of CLK1 kinases 
Thus far the only known regulator of CLK1/4 activity (aside from CLK1/4 itself) is 
the insulin signaling pathway via PI3kinase/AKT activation (Blaustein, Pelisch et al. 2005; 
Jiang, Patel et al. 2009). AKT was shown to phosphorylate CLK1, which enhanced the 
ability of CLK1 to phosphorylate at least three SR proteins. It was also demonstrated that 
CLK1/4 activity responds to insulin stimulation in hepatic cells. In this case CLK1/4 
functions to control the AS of PKCß, a key kinase that regulates fat development. 
Interestingly, PKCß splice variants encode proteins with different activities (Patel, 
Apostolatos et al. 2004; Patel, Kaneko et al. 2005; Jiang, Patel et al. 2009).  CLK2 was 
recently shown to be under the control of insulin signaling in the fasting/feeding response 
in a mouse model (Rodgers, Haas et al. 2010). Upon feeding, CLK2 protein levels are 
induced via a phosphorylation mark added by AKT. AKT-mediated phosphorylation 
stabilizes CLK2 by blocking the ubiquitin-mediated turnover of CLK2. In this scenario, it 
appears that CLK2 serves to phosphorylate and inactivate a key transcription factor 
involved in the starvation response (PGC1). PGC1 harbors an RS-like domain (as 
described above) which is required for CLK2 interaction and phosphorylation. Although 
there may be some redundancy between CLK1 and CLK2, I speculate that CLK1 controls 
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AS while CLK2 probably regulates gene expression.  Some of the biochemical differences 
between these two factors will be discussed in more detail in the results below.  
 
CLK inhibitors  
Efforts to generate small-molecule inhibitors of CLKs have seen some success. 
The small compound TG003 was developed as a selective CLK1 inhibitor but also acts 
on CLK4 and CLK2 with two- and ten- fold less specificity, respectively (Muraki, 
Ohkawara et al. 2004). TG003 was shown to disrupt AS in human cell culture systems 
and impaired the development of zebra fish. Another inhibitor of CLK1, KHCB-619, has 
shown similar efficiency as TG003 (Fedorov, Huber et al. 2011). Interestingly, several 
studies claimed that minimal loss of cell viability and growth was observed upon inhibition 
of CLK1. I address this question more thoroughly below and show that our data are in 
direct conflict.    
 
CLK homologs 
CLK kinases show some conservation in fly and yeast. In D. melanogastor, the 
CLK homologue darkener of apricot (DOA) has a well-defined role in modulating sex 
determination by regulating the AS of the sex lethal gene (Yun, Lee et al. 2000; Kpebe 
and Rabinow 2008). Additionally, DOA was identified in a genome-wide RNAi screen as 
a protein required for normal cell cycle progression; however these results have not been 
validated or assessed in mammalian cells (Bettencourt-Dias, Giet et al. 2004). It is worth 
noting that DOA is the only CLK kinase in flies and is most closely related to CLK2 by 
sequence homology. In S. pombe, Kic1 bears similarity to human CLK kinases and has 
 
 
20 
been shown to regulate both mitotic progression and splicing (Tang, Luca et al. 2011). 
Mechanistic insight regarding Kic1 regulation of either cell cycle or AS, and whether these 
two processes are coupled, is unknown. 
 
Global gene expression by CLKs  
To date, global gene regulation events responsive to CLK activity are mostly 
unknown. Most of the AS events controlled by CLK1 have been identified on a case-by-
case basis, some of which have been discussed already. Limited information regarding 
global CLK1 gene regulation has made it difficult to assign a major biological role to this 
factor. SR proteins have additional functions in translation (Michlewski, Sanford et al. 
2008), mRNA export (Escudero-Paunetto, Li et al. 2010), genome stability (Li and Manley 
2005) and more recently in oncogenesis (Ghigna, Giordano et al. 2005; Karni, de 
Stanchina et al. 2007; Karni, Hippo et al. 2008; Anczukow, Rosenberg et al. 2012).  
 
Connections between cell cycle and splicing 
 The importance of constitutive splicing for cell cycle progression has been 
observed in early screens to identify cell cycle regulators in budding yeast. Some of the 
factors identified, CDC40/PRP17, were later shown to be key pre-mRNA splicing factors 
(Ben-Yehuda, Dix et al. 2000). Similarly, in human cell lines, loss of core spliceosome 
components leads to cell cycle arrest. These results likely reflect the importance of 
properly splicing pre-mRNAs to mature mRNAs. If the loss of the core splicing machinery 
leads to the mis-splicing of even one important cell cycle regulator (i.e. Cyclins or CDKs) 
a phenotype in cell cycle progression would be expected. There is experimental support 
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for this notion. For example, the aberrant splicing of specific cell cycle regulators (p53, 
CDC25B, CDC25C and Cyclin D) due to genetic mutations or loss of splicing machinery 
components causes cell cycle defects (Ghosh, Stewart et al. 2004; Holley, Heighway et 
al. 2005; Rohaly, Chemnitz et al. 2005; Pacheco, Moita et al. 2006; Olivares-Illana and 
Fahraeus 2010; Fregoso, Das et al. 2013).  The evolutionarily conserved gene enhancer 
of rudimentary homolog (ERH) was shown cause intron retention in the key mitotic motor 
protein CENPE leading to severe mitotic defects (Weng, Lee et al. 2012). While these 
data demonstrate that splicing is required for the cell cycle, the phenotype is most likely 
a consequence of the loss of splicing as a house-keeping process. Similarly, blocking 
transcription would be expected to induce cell cycle arrest as a consequence of the loss 
of key cell cycle regulators. These observations, however general, have prompted the 
use of the general splicing inhibitor spliceostatin A for blocking tumor proliferation. 
Reportedly, this drug functions by non-covalently interacting with a protein within the 
spliceosome (SF3b) and acts as a general splicing inhibitor (Nakajima, Hori et al. 1996; 
Kaida, Motoyoshi et al. 2007).  Again, these results reflect a link between cell cycle 
progression and splicing. 
 Cell cycle stage has also been shown to regulate splicing. During mitosis, when 
transcription is shut off, the spliceosome is inactivated (Shin and Manley 2002; Blencowe 
2003).  Support for this claim emanates from the lack of in vitro splicing activity in mitotic 
nuclear extracts. Mechanistically, the SR protein SRP38 was shown to be a general 
suppressor of splicing during mitosis.  Interestingly, de-phosphorylation of SRP38 is a 
pre-requisite for the splicing suppression observed. Furthermore, removing SRP38 from 
mitotic splicing extracts restores splicing activity.  To the best of our knowledge, regulation 
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of splicing in other cell cycle stages has not been shown.   
 Above, I described a link between constitutive splicing and cell cycle control.  
Whether AS and cell cycle mutually control each other remains unclear.  Thus far, several 
studies suggest that this likely occurs. Loss of several alternative splicing regulators has 
been shown to induce cell cycle defects. Loss of SRSF1 (Li, Wang et al. 2005; Edmond, 
Merdzhanova et al. 2013), SRSF2 (Xiao, Sun et al. 2007), SRSF3 (Loomis, Naoe et al. 
2009; Kurokawa, Akaike et al. 2013) and SON (Ahn, DeKelver et al. 2011) alter cell cycle 
progression. In the case of SRSF1 and SON, it was shown that several cell cycle 
regulators were alternatively spliced into non-productive isoforms.  One study 
demonstrated that the splicing pattern of the DNA-damage checkpoint kinase CHEK1 
was dynamic during cell cycle at the protein level (Pabla, Bhatt et al. 2012).  
Moore et al. (2010) eloquently demonstrated that mitotic arrest induced by AURKA 
inhibition activated a pro-apoptotic AS network (Moore, Wang et al. 2010). This work was 
also one of the early reports demonstrating the complexity of splicing regulation by 
showing that loss of hundreds of proteins could trigger AS changes of a single gene. 
Intriguingly, a significant proportion of the genes identified were cell cycle control factors. 
A recent proteomics study revealed that the abundance of many constitutive and 
alternative splicing factors changed with cell cycle stage (Lane, Yu et al. 2013). The 
mechanism explaining these changes were not investigated, nor was the effect on AS 
regulation. As will be shown below, I demonstrate that 167 RNA-binding proteins are 
periodically expressed at the RNA level. 
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Thesis objectives 
AS has emerged as a critical mode of gene regulation and the evidence presented 
above suggest that AS regulation might be a function of cell cycle. What is lacking is a 
systematic study to determine if AS is under cell cycle periodic control. What genes (if 
any) are periodically spliced? Can we identify splicing regulators that serve to ensure 
periodic splicing occurs? What are the phenotypic consequences of disruption periodic 
AS? Can information about transcriptome-wide dynamics during cell cycle be used to 
learn something new about disease states (i.e. cancer)?  I propose the following: 
1. Uncover transcriptome dynamics during cell cycle. 
2. Identify coding transcripts that are periodically expressed. 
3. Determine if lncRNAs are periodically expressed. 
4. Determine if alternative splicing is under cell cycle control (periodic AS).  
5. Use computational approaches to identify putative regulatory mechanisms for 2, 3 
and 4. 
6. Use computational approaches to functionally classify the genes identified in  2, 3 
and 4 
7. Uncover the underlying regulatory mechanisms for AS regulation during cell cycle 
8. Determining if disrupting periodic AS leads to cell cycle defects.  
9. Use the information from our periodic transcriptome to develop a computational 
approach capable of inferring the cell cycle stage of any sample with gene 
expression data.  
10.  Develop an overarching model of transcriptome dynamics during cell cycle.   
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II. Materials and Methods 
 
Chapter III  
Cell culture and cell cycle synchronizations  
 HeLa (kind gift from J. Trejo), HEK 293T (from ATCC) and A549 (kind gift from W. 
Kim) cells were maintained in DMEM (Gibco) medium supplemented with 10% FBS 
(Gibco).  All cells were cultured in a humidified incubator with 5% CO2. Cell cycle 
synchronization was adopted from the protocol of Whitfield et al. Briefly, ~ 750,000 log 
phase HeLa cells were plated in 15 cm dishes in complete media and allowed to adhere 
for 16hrs. Cells reached < 30% confluence and were treated with 2mM thymidine (Sigma) 
for a total of 18hrs.  Treated cells were then washed 2 times with 1XPBS and allowed to 
recover in fresh complete media for 10hrs without drug. 2mM thymidine was subsequently 
added for a second thymidine treatment lasting an additional 18 hrs.  Thymidine solution 
was freshly prepared for each experiment in 1XPBS and passed through 4.5uM filter 
(Amicon).   Cells were then washed as described previously and released in complete 
medium. Collections were made every 1.5 hrs.  
 Mitotic block was performed by double thymidine arrest (exactly as above). 3.5 hrs 
after final release in fresh media, cells were treated with 100 M nocodazole (Sigma) for 
10hrs. G1 blockade was performed by serum starvation for 72 hrs in DMEM containing 
0.05% FBS. Cells were inspected visually at all steps of the protocol to ensure appropriate 
density and health of cells.  
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Cell collections  
 Cells from synchronization experiments were collected as follows: plates were 
washed two times with 1XPBS, each time all solutions coming in contact with the culture 
dish were kept to prevent the loss of the non-adherent mitotic cells. Washed plates were 
treated with 0.05% Trypsin EDTA (Gibco). Trypsin was neutralized with cell media and 
all collected liquid from each sample was pooled and spun down at 1,500 rpm. Cell pellet 
was washed with 1XPBS and was split three ways for collection of protein, RNA and flow 
cytometry.  
 
Flow cytometry and cell cycle analysis   
 Cells were collected as described above. Pellet was re-suspended in 1X 
weight/cell volume in 1XPBS and fixed in 80% ice cold ethanol (10X final cell volume) for 
at least 4 hrs (usually overnight) at -20° C. Cells were spun at 2,000 RPM at 4° C for 5 
min then washed twice with 1XPBS.  Cell pellet was re-suspended in propidium 
idodide/RNAse staining buffer (BD pharmingen). Cells were analyzed by flow cytometry 
to count 10,000 cells that satisfied gating criteria. Data collected were analyzed using 
ModFit software to discern 2N (G1), S-phase and 4N (G2 and M) composition.  
 
RNA preparations and RNA sequencing  
 RNA from synchronized HeLa cells was purified with TRIZOL reagent (Invitrogen) 
according to the manufacturer’s protocol. Purified RNA was then treated with DNAseI 
(Qiagen) on RNAeasy columns (Qiagen) according to manufacturer’s protocol. RNA 
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quality and expected size of fragment was assessed by standard gel electrophoresis and 
spectrophotometry. RNA-seq libraries were robotically prepared with the TruSeq Sample 
Prep Kit (Illumina) according to manufacturer’s protocol. Samples were prepared and 
each was barcoded at the primer ligation step for future analysis. The 14 samples were 
mixed at equal concentrations and sequenced on one full chip of HiSeq 2000 (Illumina), 
using the pair-end protocol with 100 bp read length. This approach resulted in 8 technical 
sequencing replicates per sample.  
 
Mapping and filtering of RNA-seq data  
 RNA sequencing reads were mapped to the human genome (build hg19 for gene 
expression studies and build hg18 for alternative splicing studies) using the MapSplice 
informatics tool with default parameters. Gene expression was calculated with the 
Cufflinks informatics suite and the resulting FPKM (Fragments Per Kilobase per Million 
mapped reads) values were considered to reflect transcript levels. I generated eight 
technical replicates per sample and these were mapped independently. The use of 
technical replicates made it possible to further filter data as follows: I required that the 
standard deviation across the eight independently assigned FPKM values to be no 
greater than 0.5 fold of average FPKM (i.e., genes with larger variations between 
technical replicates were discarded) per transcript. For each transcript detected in the cell 
cycle experiment, 12 out of 14 samples had to satisfy the criteria described above for 
further analysis. In the infrequent cases were one or two samples did not satisfy these 
criteria, the final FPKM value for those outlier samples was adjusted to be the average of 
the preceding and following sample (i.e. if gene expression of a gene in sample 5 does 
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not meet criteria then its gene expression value was adjusted to the mean of the gene 
expression of the same gene in sample 4 and 6).  Finally, a minimal FPKM average across 
all 14 of less than or equal to 0.5 across was set. In total 8835 genes met our filtering 
criteria and were further analyzed.  
 The levels of alternatively spliced isoforms were calculated by the MISO (Mixture-
of-Isoforms) probabilistic framework (Katz, Wang et al. 2010). For the purpose of 
consistency and library quality, the annotated alternative splicing event assembly from 
the hg18 genome build was used.  Each AS event was assigned a PSI (percent-spliced-
in) value which represents the percent of the inclusion event as detailed in the MISO 
manual. I calculated AS events for skipped exons SE, retained introns RI, alternative 
splice sites, tandem untranslated regions TUTR, and mutually exclusive exons MXE. For 
cell cycle data, I required that each detected event have a minimum of four supporting 
reads.  
 
Identification of periodic RNAs and periodic AS 
For each expressed gene, I normalized gene expression as follows: 
𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 (𝑒𝑛
𝑖 ) =  
𝑒𝑛
𝑖 − 𝐸𝑚𝑖𝑛
𝑖
𝐸𝑚𝑎𝑥
𝑖
 
, where i = 1 to 8,835 for all expressed genes; n = 1 to 14 for the14 samples; 𝐸𝑚𝑖𝑛 is the 
minimum and 𝐸𝑚𝑎𝑥 is the maximum gene expression value among the 14 samples. 
 To identify periodic genes, normalized gene expression values (i.e. 
𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 (𝑒𝑛 )) for the well-known periodic genes, CCNB1, CCNA2, CCNB2, and 
CENPE were used as a starting point for the modeling of 7 curves which have periodic 
expression. I term these “ideal seed curves.” The 7 curves capture intermittent peak times 
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and phase shifts. To identify genes that have similar expression across the cell cycle, I 
calculated the Euclidean Distance 𝐸𝐷 between each ideal seed curve and every detected 
gene as follows:  
𝐸𝐷𝑚,𝑖 = ∑ |𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 (𝑒𝑛
𝑚) − 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 (𝑒𝑛
𝑖 )|
14
𝑛=1
 
, where m = 1 to 7 for all model seed curves, i = 1 to 8,835 for all expressed genes. 
I ranked genes according increasing order of ED.  An arbitrary cutoff of 𝐸𝐷 ≤ 2.5 was 
used in this study as a minimum requirement to be classified as periodic. A requirement 
of at least 1.5 fold change between the 𝐸𝑚𝑖𝑛
𝑖  and 𝐸𝑚𝑎𝑥
𝑖  for gene i was also employed to 
reflect a significant change in expression across cell cycle.  
 For identification of periodic AS, a similar approach was employed. PSI values 
were normalized as follows: 
𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 (Φ𝑛
𝑠 ) =  
Φ𝑛
𝑠 −  Φ𝑚𝑖𝑛
𝑠
Φ𝑚𝑎𝑥
𝑠  
, where s = 1 to 32,109 for all splicing events; n = 1 to 14 for the14 samples; Φ𝑚𝑖𝑛 is the 
minimum and  Φ𝑚𝑎𝑥 is the maximum PSI value among the 14 samples. Periodicity was 
calculated utilizing the same periodic seeds and distance metric. For each AS event s, I 
computed the Euclidean Distance 𝐸𝐷 as follow: 
𝐸𝐷𝑚,𝑠 = ∑ |𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 (e𝑛
𝑚) − 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 (Φ𝑛
𝑠 )|
14
𝑛=1
 
, where m = 1 to 7 for all model seed curves, s = 1 to 32,109 for all AS events. 
A cutoff of 𝐸𝐷 ≤ 2.5 was set as a minimum requirement for periodic AS classification. I 
required that a minimum PSI change between Φ𝑚𝑖𝑛
𝑠  and Φ𝑚𝑎𝑥
𝑠  for each AS event s be at 
least 10%.  
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Heat maps, hierarchical clustering and Pearson correlation analysis  
 Heat maps, hierarchical clustering and Pearson correlations were generated using 
GENE-E (www.broadinstitute.org/cancer/software/GENE-E/). All heat maps shown are 
row-normalized for presentation purposes. DAVID 
(http://david.abcc.ncifcrf.gov/gene2gene.jsp) was used for all gene ontology enrichments. 
GO terms shown are for biological process (GOTERM_BP_FAT).  
 
Analysis of enriched motifs  
 The sequence motifs enriched in periodic AS events were identified using a 
previously described method (Fairbrother, Yeh et al. 2002). Briefly, 347 periodic SE 
events (or 192 periodic RI events) were collected and the pentanucleotide frequencies 
were calculated for fragments around alternative splice sites (ss). Intronic sequences 
immediately adjacent to ss (first 10 nt and last 25 nt of intron) were removed to avoid 
sequence bias. The frequency of each pentanucleotide near periodic AS events was 
compared to a control set of AS events.  The control sets were generated by selecting 
SE or RI events whose PSI values did not change across 14 time points, but have similar 
expression levels to the test event set. I also matched the control set with similar PSI 
distribution to the periodic events. To this end, I grouped the mean of PSI values in 
periodic events into 10 bins (i.e. 0-0.1, 0.1-0.2, 0.2-0.3, etc) and counted the number of 
events in each bin. For each bin, Irandomly selected 2 and 3 times as many events as in 
the control (for SE and RI respectively), and calculated the frequency of each 
pentanucleotide at the same positions around alternative ss.  Random selection of control 
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exons and introns was carried out 10 times, and the average frequency of each 
pentanucleotide was used to calculate pentamer enrichment as previously described 
(Fairbrother, Yeh et al. 2002).  The over-represented pentanucleotides (z cutoff 2.5) were 
aligned with clustalW2 to generated consensus motifs (Fairbrother, Yeh et al. 2002).   
 
Splicing assay with semi-quantitative RT-PCR  
 Total RNA was purified using the Trizol method (Life Technologies). Purified RNA 
was treated with 1U of RNAase-free DNAase (Promega) for 1 hour at 37ºC. ~0.5ug of 
total RNA was used for reverse transcription using random hexamers as primers with a 
cDNA preparation kit (Applied Biosystem). RT product was used as the template for PCR 
amplification (25 cycles of amplification, with trace amount of Cy5-dCTP in addition to 
non-fluorescent dNTPs) using gene specific primers listed in supplementary table S5. 
DNA was resolved on TAE gels and the resulting gels were scanned with a Typhoon 8600 
Imager (GE Healthcare). Images were analyzed with Image Quant 5.2 software 
(Molecular Dynamics/GE Healthcare). Real time PCR was carried out with SYBR Green 
kit (Applied Biosystem). 
 
Western blotting  
 Proteins were extracted in lysis buffer (CHAPS 1% w/v, 150mM NaCl, 50 mM 
MgCl2 with protease inhibitor), resolved by SDS-PAGE and transferred onto PVDF 
membranes. Table X details the antibodies and appropriate concentrations used. 
Immunoblots were developed using standard autoradiography film.  
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Chapter IV  
 
Cell culture and inhibitor treatments 
 To inhibit the activity of CLK1 or proteasome, TG003 (Sigma), KHCB-19 (Tocris) 
and MG132 (Sigma) were re-suspended in DMSO and added to growing cultures at the 
indicated concentrations. All drugs were aliquotted into 20uL of 1000X concentrated 
solutions to prevent freeze thaw cycles. 
 
Western blotting and immunoprecipitation 
  Proteins were extracted in lysis buffer (CHAPS 1% w/v, 150mM NaCl, 50 mM 
MgCl2 with protease inhibitor at pH 7.4), resolved by SDS-PAGE and transferred onto 
PVDF membranes. For ubiquitin immuprecipitation experiments, cells were co-
transfected with Flag-CLK1 and myc-ubiquitin constructs as above. 36 hours later, TG003 
(20 μM) was added to culture for 18hrs. 4 hours prior to harvest 10M of MG132 was 
added to media. Proteins were extracted and clarified in lysis buffer as above with the 
addition of NEM. Incubation with EZ-View FLAG Beads (Sigma) was performed for 2 
hours at 4ºC. Samples were extensively washed according to manufacturer’s protocol 
and resolved by immunoblot.  
 
Plasmid construction, transfections, RNAi and lentiviral infections  
 The expression constructs were generated by cloning cDNA of CLK1 into pCDNA3 
(for transient expression) or pCDH1 (for stable transfection) backbones with different 
epitope tags (HA or Flag) at N- or C-terminus. The Myc-His-Ubiquitin expression vector 
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was a gift from Dr. Gary Johnson’s lab, and the Histone H2B-GFP expression vector was 
gift from Dr. Angelique Whitehurst’s lab.  Plasmid transfections were performed using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol. The lentiviral 
shRNA vectors were obtained from Addgene (pLKO.1 TRC mammalian gene knockdown 
consortium). Lentiviral infections were performed according to Addgene’s protocol 
(plKO.1) or System Biosciences (pCDH1).  
 
High-throughput RNA sequencing and analysis 
 RNA was collected from HEK 293T cells treated with 10 M of TG003 for 18 hours. 
Samples were collected as above and the library was prepared utilizing a strand-specific 
protocol described in (Ni, Corcoran et al. 2010). Samples were sequenced on Genome 
Analyzer II (Illumina) with a read length of 75 bp. Mapping and data processing was 
performed as detailed above.  
 
Colony formation assays  
 HeLa cells stably carrying shRNAs targeting CLK1 or control shRNAs were plated 
at low density (1,000 cells/6 cm2) in standard culture medium and allowed to proliferate 
for 9 days. Cells were then fixed and stained with crystal violet at room temperature for 
15 min. Plates were washed with 1XPBS twice, dried at room temperature and 
photographed.  
 
Immunofluorescence and high-content live-cell imaging  
 For immunofluorescence, cells were plated on glass coverslips coated with poly-
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L-Lysine. Cells were then washed twice with 1XPBS, fixed with 4% formaldehyde (Sigma), 
permeabilized with 0.05% Triton X-100 (Promega) and blocked with 3% BSA (Fisher); all 
dilutions were made in 1XPBS and filtered. For live cell imaging, a HeLa cell line 
transduced with Histone H2B-GFP was stably selected as described previously (Cappell, 
Larson et al. 2010). These cells were plated in a 6-well format and subjected to thymidine 
2mM for 24hrs, subsequently washed and released in fresh complete medium with or 
without TG003 (20uM). Cells were imaged using the BD Pathway Microscope with a 10X 
objective. Images were captured every 10min and further processed and analyzed using 
ImageJ Software.  
 
Chapter V 
Databases used and data collection  
TCGA sequencing results were downloaded from: “Data Matrix - TCGA Data Portal - 
National Institutes of Health”: 
(https://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm). mRNA gene expression and 
somatic mutations data were collected. PAM50 for breast classification was provided by 
Perou lab. Embryo data was obtained from the supplementary materials provided by Yan 
et al. (Yan, Yang et al. 2013). 
 
Correlation analysis for inference of cell cycle stage 
 The expression values for the 1,184 periodic genes were extracted for each of the 
data sets to be analyzed. Before correlation analysis, gene expression values were 
initially normalized across all samples. Normalization was performed in the same way as 
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was done for the 14 cell cycle samples (Sample-min(Sample)/max(Sample)). Each data 
set used in this analysis was normalized separately. These include the 14 HeLa cell cycle 
samples, 16 normal tissue types, 150 single cell sequencing of embryos, and the TCGA 
tumors types. Therefore, subsequent correlations reflect the relative similarity as 
compared to the rest of the samples within the normalization group (i.e. testes compared 
to the other 15 normal tissues). Spearman’s Rank correlation was used for a pairwise 
analysis across all samples. For this analysis, the correlation of each sample to specific 
cell cycle stages is shown. For simplicity, four candidate samples representing G1 
(sample 7), S (sample 9), G2 (sample 11) and M (sample 5) were shown in the analyses 
of cancer data. 
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III. Transcriptome dynamics during the mitotic cell cycle 
 
 
Introduction: 
The coordination of gene function with specific cell cycle stages enables timely 
control of molecular events to ensure accurate genome duplication, chromosome 
segregation and division of daughter cells. Mis-regulation of these processes is the 
underlying cause for many human diseases, most notably cancer. Conventionally, 
periodic gene function is thought to be achieved through stage-dependent transcription 
(Bertoli, Skotheim et al. 2013), protein degradation (Nakayama and Nakayama 2006; 
Mocciaro and Rape 2012), protein-protein interactions (Satyanarayana and Kaldis 2009) 
and protein modification.  
Gene regulation extends far beyond transcription and protein degradation. 
Alternative splicing, for example, affects most (>90%) human transcripts and can 
ultimately alter protein function. Previous studies of periodic gene expression during the 
cell cycle have been limited to examining the levels of known transcripts or proteins with 
little attention paid to identify novel transcripts (e.g., non-coding RNAs) or to discriminate 
between different splicing isoforms (Cho, Huang et al. 2001; Whitfield, Sherlock et al. 
2002; Bar-Joseph, Siegfried et al. 2008; Olsen, Vermeulen et al. 2010; Lane, Yu et al. 
2013). While microarrays have been very useful in determining the changing levels of 
known mRNAs during cell cycle, these assay fail to provide information regarding splicing 
and are incapable of detecting transcripts that have not yet been annotated.  
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AS is an integral mode of gene regulation that controls key biological process 
including development and cellular differentiation (Gabut, Samavarchi-Tehrani et al. 
2011; Han, Irimia et al. 2013; Xue, Ouyang et al. 2013), raising an important question: is 
AS is coordinated with cell cycle stages?  Previous studies have implied that splicing 
regulation may be affected by cell cycle. For example, the abundance and 
phosphorylation of some splicing factors exhibit cell cycle-associated dynamics (Gui, 
Lane et al. 1994; Lane, Yu et al. 2013) and loss of specific splicing factors was found to 
induce cell cycle arrest (Ahn, DeKelver et al. 2011; Kurokawa, Akaike et al. 2013). In 
addition, mitotic arrest induced by AURKA inhibition leads to the activation of pro-
apoptotic splicing of Bcl-X and Mcl-1 (Moore, Wang et al. 2010). Furthermore, it is known 
that splicing is inhibited during mitosis, consistent with the general inactivation of 
transcription during this cell cycle stage (Shin and Manley 2002). However, the 
relationship between global coordination of AS and the cell cycle has not been 
systematically investigated. 
Here I report the dynamic transcriptome at single-nucleotide resolution through two 
unperturbed cell cycles. A simple, yet robust computational analysis method was used to 
identify periodic gene expression. Over 1,000 cell cycle-dependent transcripts, including 
40 periodically expressed long non-coding RNAs were found. Surprisingly, I uncovered 
widespread coordination of periodic alternative splicing with cell division, which presents 
a novel regulatory mode for cell cycle progression. Our findings reveal a novel mechanism 
for periodic regulation of gene function during specific cell cycle stages, which adds to the 
previously known mechanisms involving transcription and protein stabilization.  
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Results 
Sequencing the cell cycle-dependent transcriptome 
I optimized a double thymidine block cell synchrony protocol which generates a 
highly-synchronous culture of cells arrested very early in S-phase. Importantly, this 
protocol has been shown to cause minimal activation of the DNA damage response (data 
not shown). I chose chemical synchrony because other methods, including serum 
starvation, lead to the activation of gene expression networks that drive diverse cellular 
pathways not relevant to cell division (i.e. wound-healing response).  Synchronously 
dividing HeLa cells were sampled every 1.5 hours after early S phase release for 36 hours 
(about 2.5 cell divisions). Cellular DNA content was measured at each sampling point by 
propidium iodide staining and flow cytometry to assess cell cycle stage (Figure 3.1). 
Immunoblotting of eight well-known cell cycle markers that have peak expression across 
all four phases of the cell cycle displayed the expected expression patterns (Figure 3.2 
A). These data demonstrated a high-degree of cell synchrony after application of this 
protocol. 14 samples were selected to match samples between the first and the second 
round of division. Meaning, sample 1 from the first cycle matches sample 7 of the second 
cycle (2 matches 8 and so forth). For each sample I prepared a cDNA library from poly-
adenylated RNAs and sequenced each library with a depth of 100-250 million paired-end 
reads (Figure 3.2 C). 2.3 billion 100-nt reads were obtained after sequencing by Illumina 
technology (HiSeq 2000) as detailed in (Table 3.1). Data was quality scored and mapped 
to the human genome using the MapSplice informatics tool with default parameters 
(Wang, Singh et al. 2010). Most of the sequencing reads >95% were of high-quality and 
mapped uniquely to the human genome (Table 3.1). Our dataset represents eight 
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technical replicates per sampling point. Further analysis was performed using Cufflinks, 
a bioinformatics tool capable of accurately calculating the abundance of transcripts arising 
from each gene (Trapnell, Williams et al. 2010). FPKM values (fragments per kilobase of 
transcript per million mapped reads) were used as the expression value for each gene. 
~9,000 transcripts met our stringent filtering criteria (see methods) set to discriminated 
against transcripts with poor consistency across technical replicates or with low 
expression level.   
 
Identification, function and regulation of periodic genes 
I next addressed if I could determine periodic gene expression patterns in this 
dataset. I extracted FPKM values (expression values) for known periodic transcripts 
including CCNE, CCNB1, CCNB2, and CCNA2 and found they exhibited the expected 
expression pattern with robust changes across all cell cycle phases (Figure 3.2 C). I next 
focused on identifying all periodically expressed RNAs in the cell. To this end, seven 
periodic seed curves with varying peak expression were modeled based on the 
expression dynamics of known cycling genes (Figure 3.2 C).  Importantly these seven 
modeled curves represent peak expression at all major cell cycle phases (see methods). 
I employed a simple Euclidean distance metric to calculate similarity between the gene 
expression curves (the 14 expression values during cell cycle) of any gene to the ideal 
seed curves (see methods). Using an arbitrary score for periodicity, I uncovered 1,182 
periodically expressed transcripts that were broadly distributed across all cell cycle 
phases (Figure 3.2 D and E). 
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In addition to detecting known protein coding genes, transcriptome profiling by 
RNA-seq enables the unbiased detection of any RNA harboring a polyadenylated tail. 
The long non-coding RNAs (lncRNAs) are emerging as class of factors that control 
development and cell proliferation (Batista and Chang 2013; Yoon, Abdelmohsen et al. 
2013). To examine if the expression of lncRNAs is periodic, I mapped our reads to the 
annotated lncRNA database (see methods). Out of ~400 lncRNAs with sufficient read 
coverage, 40 were identified as periodically expressed, including the known cell cycle-
dependent lncRNA MALAT1 (Tripathi, Shen et al. 2013) (Figure 3.2 F and G). The fact 
that I captured a previously reported periodic lncRNA indicates the sensitivity of our 
approach. This analysis strongly suggests that periodic lncRNAs may play previously 
unappreciated roles in cell cycle regulation. 
To further investigate the function periodic genes I classified them into three 
groups (G1-S, G2-M and M-G1) according to their peak expression stage. I first analyzed 
the concordance between peak expression stage and gene function. As expected, all 
three groups are enriched ontologies in cell cycle progression, although the specific 
molecular functions differ (Figure 3.3 A).  For example, genes in G1-S group were 
enriched for functions related to “DNA metabolic process” (p= 6x10-13). Among these 
genes are many DNA pre-replication factors, components SCF complex and DNA repair 
genes.  While the G2-M group was highly enriched for the “M phase” ontology (p= 5x10-
37), including genes encoding key mitotic factors like members of the MCC, APC and 
components of the spindle assembly checkpoint. Interestingly, the group representing the 
M-G1 stage was enriched for RNA processing factors including some key splicing 
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regulators, suggesting extensive regulation of RNA processing during this stage (Figure 
3.3 A).  
I next determined putative transcription factors that may control gene expression 
levels during each of the three expression groups by analyzing the promoters of periodic 
genes (see methods). As expected, the promoters of the G1-S group contained the 
binding sites for cell cycle-related transcription factors such as E2F motifs (p= 1.8x10-19). 
These data are consistent with the known roles of E2F family members in regulating the 
G1/S transition. In fact, 18 out of the top 20 motifs identified were related to the E2F family. 
The top motifs for G2-M genes included binding sites for SP1, NFY, LEF1 and FOXO4 as 
well as unknown motif (i.e. AACTT). The M-G1 had very modest enrichments, likely due 
to the small number of genes in this cluster.  In total, 164 putative transcription factor-
binding motifs were identified. To address whether the different waves of transcription 
G1-S vs. G2-M may be regulated by a non-overlapping mechanism, I compared the 
transcription factor binding motifs in each group. A modest overlap of only 9 motifs was 
observed, suggesting a global difference in transcriptional regulation during these two 
stages of cell cycle (Figure 3.3 B and C).  
Using bioinformatics tools (see methods), extensive protein-protein interactions 
were also found among periodic genes, including key cell cycle-control complexes like 
anaphase promoting complex, the kinetochore and the pre-replication complex (data not 
shown). Taken together, I identified a large set of periodically expressed coding and non-
coding transcripts, many of which have not yet been implicated in cell division or have 
unknown functions. 
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Consistency across datasets 
 Hundreds of periodic transcripts have previously been identified using microarrays 
across different cell types (Whitfield, Sherlock et al. 2002; Bar-Joseph, Siegfried et al. 
2008). I sought to investigate the how consistent our periodic gene signature is when 
other compared to those in other cell types. I first compared our data to another study 
that also employed HeLa cells and found that our dataset covered ~40% of periodic 
transcripts previously reported. It is worth noting that our approach captured most of the 
highest ranking periodic transcripts according to Whitfield et al (80 out of the top 100 
periodic genes were captured) (Whitfield, Sherlock et al. 2002).  A strong correlation 
between the rank of periodic score (a measure of how periodic an RNA is) and likelihood 
of overlap was observed (Figure 3.3D). I next examined the concordance between this 
study and 4 other independent studies. A striking find was that although roughly 2,500 
different transcripts have been classified as periodic, only 67 of these are consistent 
across all cell lines investigated. Furthermore, these 67 appear to have specialized mitotic 
functions. This observed variability can be explained by intrinsic differences in cell lines 
used, techniques applied (i.e. microarray vs. RNA-seq), and culturing conditions.  
This modest overlap across different studies prompted us to further investigate the 
functions of 953 novel periodic transcripts presented in this study. Strikingly, “new” 
periodic transcripts appear to have very similar characteristics (i.e., enrichment of gene 
functions and transcription factor binding motifs) as the entire set of periodic transcripts 
identifying (Figure 3.3 E). This result suggests that some of the observed differences 
between this study and others are likely a consequence of sampling bias from 
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experimental conditions and/or computational analyses rather than by a high false 
positive rate. 
 
Identification of periodic alternative splicing  
Splicing is generally inhibited during mitosis (reviewed in (Shin and Manley 2002) 
and previous reports have implied that AS may be affected by cell cycle (Ahn, DeKelver 
et al. 2011; Kurokawa, Akaike et al. 2013; Lane, Yu et al. 2013). However the relationship 
between global coordination of AS and the cell cycle has not been systematically 
investigated. Transcriptome sequencing of synchronous cells enables the unbiased 
examination of cell cycle-dependent AS at a global scale.  To this end, I extracted all 
annotated AS events and calculated the percent spliced in (PSI) of each event using the 
mixture of isoforms (MISO) probabilistic framework (Katz, Wang et al. 2010). I applied the 
same periodic seed curves and similarity metrics as in Figure 1C to identify any cell cycle 
stage-dependent AS events (see methods). This approach led to the identification of 886 
periodic AS events in 728 genes covering all major AS types (Figure 3.4 A, B and C). 
Only 8% of periodic AS events (98 genes) occurred in genes with periodic expression — 
suggesting a new prevalent mechanism for periodic control of mRNA, independent of the 
fluctuations in total mRNA expression levels (Figure 3.4 D). This finding is somewhat 
surprising given that most splicing occurs co-transcriptionally and can be regulated by 
factors that control transcription (Kornblihtt, Schor et al. 2013). When I further analyzed 
the promoters of periodically spliced genes, I found that they were not enriched for cell 
cycle-dependent transcription factor binding motifs (data not shown). These observations 
 
 
43 
suggest that periodic splicing presents a novel mechanism for temporal fluctuation of 
gene function and is mostly regulated independently from transcription. 
 To examine the function of periodically spliced genes, I performed GO analysis 
and found that these genes are enriched for cell cycle-related functions including M-phase, 
nuclear division and DNA metabolic process (Figure 3.4 E) This finding indicates that 
temporal regulation of AS may play a role in the control of cell cycle progression.  I further 
analyzed the transcripts that are periodically spliced (but not periodically expressed) vs. 
those that showed both periodic expression plus AS, and again found cell cycle-related 
functions.  These results imply that many cell cycle-related genes previously thought to 
be invariably expressed may in fact function periodically due to the temporal regulation of 
AS. Using semi-quantitative RT-PCR, I validated a set of periodic AS events with known 
functions in cell cycle progression (including BORA, AURKB, HMGB2A, CHEK2 and 
HMG20B), confirming that our approach can reliably identify periodic AS events (Figure 
3.4 F) 
For genes whose splicing and expression are both periodically regulated, the AS 
fluctuations and total transcripts fluctuations frequently occurred in different phases. For 
example, the removal of retained introns in AURKB, a critical mitotic kinase, had a phase 
shift that lagged behind the total expression level. I corrected the absolute levels of protein 
coding AURKB mRNA by taking into account the fraction of intron-retaining (non-
functional) transcripts across time (Figure 3.5 A). The expression curve for corrected 
AURKB mRNA was substantially different from the total mRNA levels with a shifted peak 
at mitosis. These findings support a model in which a splicing lag may impart additional 
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control of protein production and fine-tune expression timing of functional transcripts 
(Figure 3.5 B). 
 
Putative cis-elements and trans-factors that regulate periodic AS 
Generally, AS is regulated by multiple cis-acting splicing regulatory elements 
(SREs) that recruit cognate splicing factors to influence splicing outcomes. To identify 
specific RNA sequence motifs that might regulate periodic splicing, I computed the 
frequency of all possible RNA pentanucleotides in periodically spliced transcripts 
(Fairbrother, Yeh et al. 2002).  I identified 14 putative SRE motifs that were statistically 
enriched near periodic alternative exons or introns compared to a set of control alternative 
exons and introns with similar expression levels (Figure 3.5 C and D).  These motifs were 
highly variable, suggesting that periodically spliced pre-mRNAs are recognized by various 
RNA binding proteins (RBPs).  In addition, distinct putative SREs were identified in 
different regions of periodically spliced pre-mRNAs. These data reflect the regulatory 
complexity of periodic splicing which is likely controlled by multiple RBPs in a context-
dependent fashion (Wang and Burge 2008).   
I sought to identify RBPs that may control periodic AS by examining RBPs whose 
expression level is controlled in a cell-cycle dependent fashion.  To this end, I used data 
from two independent systematic studies that aimed at identifying all RBPs in human cells 
(Baltz, Munschauer et al. 2012; Castello, Fischer et al. 2012). Out of the 1,178 identified 
RBPs, 167 were found to be periodically expressed (96 genes) or spliced (84 genes) 
(Figure 3.5 E and F).  I examined the function of these RNA-binding proteins, and found 
that many RNA processing pathways are regulated by periodically expressed RBPs 
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(Figure 3.5 G), with RNA-splicing being the most significantly enriched pathway (p= 
2.4x10-11).   These initial findings suggest that context-dependent interactions between 
cis-elements and trans-factors are involved in the control of periodic splicing. In addition 
to computational analyses, I also used experimental approaches to identify putative 
regulatory factors that control AS during cell cycle. The abundance of various proteins 
with known splicing regulatory roles was measured in synchronized HeLa cells by 
immunoblotting. Among the proteins tested, the CDC-like kinase 1 (CLK1, an SR protein 
kinase) displayed robust cyclic expression peaking at G2/M phase. These observations 
will be the subject of further investigations in the following chapter.  
 
Discussion 
I have generated a high-resolution map of the human transcriptome during the 
mitotic cell cycle. More than one thousand periodic coding and non-coding transcripts 
were identified, many of which have not been previously identified with microarray-based 
methods (Whitfield, Sherlock et al. 2002; Bar-Joseph, Siegfried et al. 2008) (Figure 3.2 D 
and Figure 3.3 D).  Despite subtle differences in experimental conditions, detection 
techniques (microarray vs. RNA-seq) and cell lines used, these independent studies 
capture transcripts with strong periodic expression, but differentially detected those with 
less robust periodic expression (Figure 3.3 D and further discussed in the introduction). 
Interestingly, the promoters of newly identified periodic genes contain motifs that are 
typically bound by cell cycle-related transcription factors. These data indicate that the 
these newly identified periodically expressed genes are not false positives. In addition, 
about 10% of lncRNAs that were analyzed are periodically expressed (Figure 3.2 F and 
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G).  Since most lncRNAs are expressed at low levels, it is likely that our stringent 
expression level filter (400 of ~13,000 predicted lncRNAs passed our initial filter) led to a 
conservative estimate of cycling lncRNAs.  These data lead us to speculate that many of 
these non-coding transcripts may play key roles in cell cycle control, as exemplified by 
the recently identified periodic lncRNA MALAT1 (Tripathi, Shen et al. 2013).   
I uncovered widespread temporal regulation of splicing during cell cycle: greater 
than 800 AS events are coordinated with cell cycle stage (Figure 3.4).  Since AS is largely 
tissue specific (Wang, Sandberg et al. 2008), it remains an open question whether the 
AS events identified in this study are generalizable to other tissue and cell types. However, 
many periodically spliced genes have cell cycle-related functions that have been 
annotated across many cell types, leading us to speculate that AS is a general regulatory 
layer of cell cycle control. Temporal regulation of AS can alter the protein-coding potential, 
as was the case for AURKB where the periodic intron retention introduces a pre-mature 
stop codon. Therefore AS presents a prevalent mechanism for periodic regulation of 
protein production independent of total RNA levels.  Recent studies have demonstrated 
that intron removal can rapidly induce protein expression (Ninomiya, Kataoka et al. 2011). 
One possibility is that while total transcripts are produced constantly across cell cycle, 
stage-dependent post-transcriptional intron removal enables a more rapid and precise 
control of protein expression. 
Little overlap was observed between periodically spliced and periodically 
expressed genes, suggesting that AS and transcription may be independently regulated 
in this context. This is an interesting observation given that most splicing events occur co-
transcriptionally (Brugiolo, Herzel et al. 2013; Kornblihtt, Schor et al. 2013). The presence 
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of putative cis-regulatory motifs in periodically spliced exons and introns is suggestive of 
regulatory mechanisms at the splicing step of mRNA production. An alternative 
explanation for the observation of periodic isoforms is that that splicing isoforms from the 
same gene are produced constantly at all cell cycle stages, but differentially degraded at 
specific stages. Based on the number of RBPs (167) that are periodically expressed 
(Figure 3.4 E, F and G), it is likely that most aspects of RNA-processing (e.g. both splicing 
and degradation) are coordinated with cell cycle stage.  
48 
 
 
 
 
 
Figure 3.1.Cell cycle analysis of synchronized HeLa cells. (A) Histograms of DNA 
content in synchronous HeLa cells upon G1/S release.  DNA was detected by propidium 
idodide (PI) staining and analyzed using ModFit software to discern 2N (G1, shown in 
red), S-phase (shown in grey), and 4N (G2 and M, shown in red) cells.   
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Figure 3.2. Periodic mRNA expression during cell cycle. (A) Cell synchronization 
confirmation by quantification of DNA content (upper bar graph) and immunoblotting of 
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cell cycle markers. (B) RNA-sequencing read counts across 14 samples aligned by 
inferred cell cycle stage. (C) Relative expression of known cell cycle transcripts from RNA-
seq data and heat map representation of ideal periodic seeds extracted from the known 
periodic transcripts. Periodic seeds are color-coded (left bar) and row-normalized. (D) 
Phase distribution of periodic genes (E) Heat map representing 1182 periodic transcripts.  
The color bar on the left represents seven periodic seed curves to which the identified 
periodic transcripts are matched (Euclidean distance  2.5), and the right colored bar 
represents the general peak expression stages. (F) Periodic lncRNAs represented as a 
heat map (left panel for 38 lncRNAs with unknown function) or as normalized expression 
curves (right panel, CCNB1 as a reference).   
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Figure 3.3. Periodic mRNA regulation and function. (A) Gene ontology terms enriched 
in periodic genes as grouped by peak stage. (B) Transcription factor binding motif 
enriched in promoters of periodic genes as grouped by peak stage or (as indicated). (C) 
Venn diagram representing the overlap in transcription factor binding motifs.  These 
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motifs are identified using in all 1182 (red), G1-S (blue) and G2-M (green).  (D) Venn 
diagram showing the overlap of periodic genes identified by Whitfield et al, Bar-Joseph et 
al, and this study (left). Percent overlap ordered by Whitfield rank score (right). (E) 
Transcription factor enrichment analysis on 1001 newly identified transcripts. 
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Figure 3.4.  Pervasive cell cycle-dependent alternative splicing.  (A) Heat map of 886 
periodic AS events ordered by periodic seed match; left bar color-codes the periodic seed 
used to identify these events (same as Figure 1C). (B) Distribution of the periodic AS 
events by type. SE: skipped exon, RI: retained intron, A3E: alternative 3’ exon, A5E: 
alternative 5’ exon, MXE: mutually exclusive exon, TUTR: tandem UTR. (C) Phase 
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distribution of periodic alternative splicing events according to similarity to each of the 
seven periodic seed curves. (D) Venn diagram showing overlap between periodically 
spliced genes and the periodic mRNAs. (E) Gene ontology terms for gene with periodic 
AS events are presented by heat map according to -log(p value). The genes with periodic 
AS events were analyzed separately in three sets: all genes with periodic AS, genes with 
periodic AS only, and genes with both periodic AS and periodic expression. (F) Validation 
of periodic AS events by semi-quantitative PCR.  
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Figure 3.5.  Cell cycle-dependent alternative splicing alters protein coding potential.  
(A) Example of periodic intron retention in the AURKB gene and the predicted effect on 
functional mRNA levels across the cell cycle. (B) Examples of periodic intron retention 
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with different phase from total mRNA phase. (C and D) Over-represented sequence 
motifs near periodically skipped exons (positions as diagramed). (E) Venn diagram 
showing overlap of all RNA binding proteins with periodic expression or periodic splicing 
during cell cycle. (F) 96 periodically expressed genes encoding RNA binding protein are 
represented as a heat map. (G) Gene ontology analysis of periodically expressed or 
spliced genes that encode RNA binding proteins.  
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IV. CLK1 kinase controls cell cycle processes via an alternative splicing network. 
 
Introduction 
CLK kinases were originally discovered due to their similarity to CDK1, but have 
not been implicated in cell cycle regulation (Johnson and Smith 1991). In humans CLK1-
mediated SR protein phosphorylation has been shown to regulate the AS of genes that 
control blood coagulation (TF) (Schwertz, Tolley et al. 2006), insulin signaling (PKCbeta) 
(Jiang, Patel et al. 2009; Li, Carter et al. 2013), and angiogenesis (VEGFA) (Nowak, 
Woolard et al. 2008). Recent reports have identified CLK kinases as factors that control 
viral infection by mechanisms that include AS regulation of viral mRNAs (Yomoda, Muraki 
et al. 2008; Escudero-Paunetto, Li et al. 2010; Karlas, Machuy et al. 2010; Wong, 
Balachandran et al. 2011). However, global gene regulation events responsive to CLK 
activity in human cells are mostly unknown. Furthermore, a general role for CLKs kinases 
in controlling biological processes, besides isolated AS events, remains undefined.  
In D. melanogastor, the CLK homologue darkener of apricot (DOA) was identified 
in a genome-wide RNAi screen as a protein required for normal cell cycle progression; 
however these results have not been validated or assessed in mammalian cells. In S. 
pombe, Kic1 bears similarity to human LAMMER kinases and has been shown to regulate 
both mitotic progression and splicing. However, mechanistic insight regarding how Kic1 
regulates either cell cycle or AS and if these two processes are coupled to elicit a 
phenotype is completely unknown. 
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Recent evidence indicates that canonical SR protein phosphorylation can be 
dynamically regulated in response to osmotic stress, heat shock and genotoxic stress. 
Importantly, dynamic SR protein phosphorylation elicits rapid signal-dependent changes 
in AS that control phenotypic outputs such as cell death.  Additionally, one study has 
demonstrated that SR protein phosphorylation is cell cycle stage-dependent with a 
general increase in canonical SR protein phosphorylation during mitosis.  
Here I demonstrate that that CLK1 kinase protein levels fluctuate during the cell 
cycle and uncover the mechanistic details of CLK1 protein turnover. I profiled the 
transcriptome in response to CLK activity and found that CLK-regulated genes have 
functions in processes such as RNA splicing, mitotic cell cycle and DNA damage 
repair/response. I show that a significant fraction of CLK-responsive genes overlap with 
those I identified as being periodic expressed and spliced (Chapter III). Furthermore, 
disruption of CLK1 activity in synchronized cultures leads to AS decisions which are 
different than those in synchronous cultures with active CLK1.  Phenotypically I 
demonstrate that inhibition or depletion of CLK1 disrupts cell cycle progression marked 
by pleotropic mitotic defects and cell death. Taken together, these data indicate CLK1 is 
a master regulator of cell cycle-related AS.  
 
Results 
CLK1 is cell cycle regulated 
As noted previously (Chapter III, Results), I measured the abundance of various 
proteins with known splicing regulatory roles in synchronized HeLa cells by 
immunoblotting (Figure 4.1 A and B). Among the proteins tested, CLK1 displayed robust 
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cyclic expression with a peak G2/M phase (Figure 4.1 A and B). The levels of CLK2, a 
highly similar kinase, as well as other SR protein kinases (SRPK1 and SRPK2) did not 
significantly change in expression during the cell cycle.  In addition, no significant change 
in the total protein levels of various splicing factors was detected across the cell cycle 
(Figure 4.1 A). However, I were able to reproduce a previous result (Gui, Lane et al. 1994) 
that showed an increase in the phosphorylation status of SR proteins at the G2/M 
transition (DD and ZW).  These data implicate that CLK1 may be the kinase responsible 
for SR protein phosphorylation changes during the cell cycle.  I speculate that CLK1 may 
have a specialized role in controlling cell cycle-dependent AS. 
 
CLK1 protein turnover  
To determine how CLK1 periodic expression is controlled, I measured CLK1 
mRNA levels at each stage and found that total mRNA levels, as well as specific splice 
variants of CLK1, remained constant throughout all cell cycle stages (Figure 4.1 C and 
D). These data indicate that periodic expression of CLK1 is likely regulated through 
protein translation or protein degradation rather than at the RNA level. To test this, I 
generated a cell line stably expressing CLK1 from a constitutive promoter (CMV). In 
agreement with our hypothesis, the exogenously expressed CLK1 protein also showed 
cell cycle-dependent fluctuations similar to the endogenous protein (Figure 4.1 B). These 
data suggest that CLK1 is likely controlled by protein turnover, presumably by ubiquitin-
mediated degradation. Consistently, CLK1 was rapidly degraded upon inhibition of 
translation by cycloheximide, and this effect was reversed by co-treatment with the 
proteasome inhibitor MG132 (Figure 4.1 E). Furthermore, polyubiquitinated flag-tagged 
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CLK1 was readily detected in immunoprecipitation experiments using extracts from 
MG132-treated cells (Figure 4.2 F). Altogether these data suggest that CLK1 protein is 
controlled by ubiquitin-mediated turnover in a cell cycle-dependent manner. 
 
CLK1 is engaged in negative feedback auto-regulatory loop  
As discussed above, periodic protein levels are frequently under the control of 
auto-regulatory feedback loops. CLK1 has been shown to auto-phosphorylate at several 
residues.  During the course of experimentation I observed that inhibition of CLK1 kinase 
activity with a selective inhibitor, TG003 (Muraki, Ohkawara et al. 2004), robustly 
stabilized endogenous CLK1 proteins (Figure 4.2 A). This effect can in part be explained 
by the fact that inhibition of CLK1 kinase activity leads to the production of primarily 
functional splice variants of CLK1, thereby increasing total CLK1 protein levels. Indeed, I 
noted a robust shift in the AS of CLK1 to variants that encode the full length protein upon 
TG003 treatment (as will be discussed below). However, the change in protein levels was 
so robust and turned over very rapidly after inhibitor washout (data not shown) that it 
prompted us to speculated that there may be another layer of regulation that accounts for 
the dramatic increase protein levels.   
To examine this further, I treated cells exogenously expressing CLK1 with TG003 
and observed a robust stabilization effect of CLK1 (Figure 4.2 A, lower panels). Plasmid-
driven CLK1 transcripts cannot be processed at the RNA level (as the cDNA contains no 
introns) indicating that this regulation is likely occurring at the protein level.  To test if 
TG003-mediated stabilization of CLK1 was indeed due to kinase activity, I generated a 
point mutant of CLK1 by mutating a conserved lysine to an arginine at position 189 (CLK1 
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KD) which has been previously shown to abrogate catalytic activity. The activity-
dependent de-stabilization was only observed with wild type (WT) CLK1 and not a kinase 
dead (KD) mutant (Figure 4.2 A). This suggests that the degradation of CLK1 is kinase 
activity-dependent. I further examined protein stability and found that while the WT CLK1 
was rapidly degraded upon cycloheximide treatment, the KD CLK1 was much more stable 
under identical treatment conditions (Figure 4.2 B).  Next I asked if CLK1 activity alone 
was sufficient to promote its own degradation. To this end, I co-expressed CLK1 KD with 
increasing amounts of WT CLK1. I expected that CLK1 WT would act in trans to trigger 
the degradation of the CLK1 KD form.  Consistently, I found that increasing amounts of 
WT CLK1 reduced the levels of KD CLK1 (Figure 4.2 C). 
Consistent with these data, WT CLK1 was more strongly polyubiquitinated 
compared to the KD form (Figure 4.2 D), and treatment with TG003 reduced the levels of 
polyubiquitination (Figure 4.2 D, lane 2 vs. 3 and lane 4 vs. 5).  The decrease of 
polyubiquitination in WT CLK1 is more than what it appears upon TG003 treatment, as 
CLK1 is stabilized by TG003 inhibition and thus more total Flag-CLK1 was precipitated  
(Figure 4.2 D, middle panel).  To further examine whether this auto-feedback loop is 
required for the cycling of CLK1 protein during cell cycle, I treated synchronized cells with 
TG003 or DMSO control and measured CLK1 protein levels. I found that CLK1 inhibition 
prevented turnover of this kinase after G2/M phase for both endogenous and exogenous 
CLK1 (Figure 4.2 E and F).  Taken together, these results suggest that CLK1 protein 
levels are controlled by ubiquitin-mediated proteolysis in a cell cycle stage-specific 
manner and that an activity-dependent negative feedback loop is required for CLK1 
periodic expression.  
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CLK1-mediated transcriptome regulation  
To date, the global effect of CLK1 activity on gene expression has not been 
systematically determined. To identify endogenous AS events regulated through the 
CLK1 pathway, I sequenced total polyadenylated RNA from HEK cells treated with the 
CLK1 inhibitor (TG003) or solvent control (DMSO).  I obtained over 40 million sequencing 
reads per sample and found 711 genes whose expression level was affected by CLK1, 
most of which increased their expression level upon CLK1 inhibition (Figure 4.3 A).  
Importantly, inhibition of CLK1 affected the splicing of 783 AS events (in 584 genes) that 
covered all major AS types (Figure 4.3 B), reconfirming the functions of CLK1 as a major 
AS regulator (Duncan, Stojdl et al. 1997; Prasad, Colwill et al. 1999; Jiang, Patel et al. 
2009). Additionally, previously known CLK1-regulated splicing events (i.e. exon 4 of CLK1 
(Duncan, Stojdl et al. 1997)) were identified as top hits in this dataset, verifying the 
sensitivity of this analysis.   
Strikingly, I found that the CLK1-regulated AS events are enriched in genes that 
function in cell cycle, RNA splicing/processing, M-phase, and DNA metabolic processes 
(Figure 4.3 D).  The enrichment of RNA processing is not surprising because CLK1 is a 
key enzyme that controls splicing factor activity.  However, enrichments in cell cycle-
related genes suggested that CLK1 may be a functional link between alternative splicing 
and the regulation of cell cycle.  To further address this question, I compared the genes 
that exhibit periodic AS with those that contain CLK1-regulated AS events and found an 
overlap of 73 genes (Figure 4.3 E), which is significantly more than expected by chance 
(p<0.35×10-5, hyper-geometric test).  In comparison, the overlap between the periodic 
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expression and the CLK1-regulated AS events is not significantly different from what is 
expected by chance (p=0.32, hyper-geometric test), further supporting a role for CLK1 in 
regulating cell cycle related AS.  
I selected individual AS events for validation with RT-PCR and were able to confirm 
these changes (Figure 4.3 C, 4.4 A and B).  To further validate our findings, I over-
expressed wild type and kinase dead CLK1 and examined changes of AS in selected 
targets (Figure 4.4 B). As expected, over-expression of WT CLK1, but not KD CLK1 
changed TG003-regulated events in the predicted direction (Figure 4.3 C).   
I next applied statistical enrichment to identify sequence motifs enriched near CLK1-
regulated exons (Fairbrother, Yeh et al. 2002) and found that exons promoted or inhibited 
by CLK1 were associated with distinct RNA motifs (Figure 4.4 C), suggesting CLK1 
functions through multiple splicing factors with different RNA binding specificities. 
 
CLK1 controls CENPE alternative splicing 
One of the newly identified cell cycle-related CLK1 targets is CENPE (centromere-
associated protein E), a kinetochore-associated motor protein that functions in 
chromosome alignment and segregation during mitosis (Kim, Heuser et al. 2008; Kim, 
Holland et al. 2010; Huang, Wang et al. 2012). CENPE was previously reported to peak 
at G2/M phase (Yen, Li et al. 1992) and was identified as a periodic transcript in our 
mRNA-seq study. CENPE pre-mRNAs are alternatively spliced to generate a long and 
short isoform; in control cultures, the predominant variant is the short mRNA which lacks 
an exon encoding amino acids 1972-2068 (Uniprot # Q02224-3). I found that the 
alternative splicing of CENPE requires CLK1, as the inhibition of CLK1 with TG003 
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substantially shifted CENPE splicing to produce mostly the long isoform (Figure 4.5 A and 
B). Inhibition of CLK1 also substantially reduced CENPE protein levels during G2/M 
phase, presumably by controlling CENPE transcript processing (Figure 4.5 C). These 
data suggest that the dynamic behavior of AS during cell division is in part controlled by 
CLK1. 
 
CLK1 and SFRS1 regulate CHEK2 AS 
Given the enrichment of cell cycle and DNA damage response genes in our RNA-
seq data, I further examined another Clk1-regulated AS event. CHEK2 is a key DNA 
damage-sensing kinase whose activity controls cell cycle progression (Nevanlinna and 
Bartek 2006; Paronetto, Minana et al. 2011). CHEK2 AS can produce variants lacking 
kinase activity or that localize differently from canonical CHEK2 protein (Staalesen, Falck 
et al. 2004). Recently, CHEK2 AS was shown modulate the DNA-damage response in 
Ewing sarcoma (Paronetto, Minana et al. 2011). Staalsen et al. identified over 50 CHEK2 
variants in human breast tumor samples (Staalesen, Falck et al. 2004). Several 
alternative exons encode the kinase domain of CHEK2 (Staalesen, Falck et al. 2004). For 
example, exon 9 encodes the amino acids required for ATP binding (Figure 4.6 A). I 
measured an increase in exon 9 inclusion after depletion or inhibition of CLK1 (Figure 4.6 
B). Conversely, over-expression of CLK1 WT, but not CLK1 KD, increased exon9 
skipping (Figure 4.6 C).  The most probable mechanism by which CLK1 could influence 
CHEK2 AS is by phosphorylating an SR protein substrate whose target RNA sequence 
lies within the CHEK2 pre-mRNA. I scanned the CHEK2 sequence near exons 8, 9 and 
10; several putative SFRS1 binding sites were predicted by the ESE Finder informatics 
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tool (data not shown). SFRS1 is an in-vitro and in-vivo substrate of CLK1 and CLK1-
mediated phosphorylation of SFRS1 regulates its splicing activity and localization (Ghosh 
and Adams 2011). To test if SFRS1 regulates exon 9 inclusion, I depleted cells of SFRS1 
by RNAi which caused an increased exon 9 inclusion while SFRS1 over-expression 
enhanced exon 9 skipping (Figure 4.6 C).  In preliminary work, I demonstrated that CLK1 
functions through SFRS1. In the absence of SFRS1 (by RNAi), Clk1 was no longer 
sufficient to regulate CHEK2 splicing (data not shown). 
 To further confirm these results, a CHEK2 splicing mini-gene was created by 
cloning the intact 5 kilobase genomic CHEK2 fragment between exons 8 and 10.  The 
splicing pattern of the resulting mini-gene was similar to that of endogenous CHEK2 and 
was regulated by CLK1 and SFRS1 in the same fashion. Putative SFRS1 binding motifs 
were mutated in this mini-gene in an effort to disrupt regulation by SRSF1. While these 
mutations had an effect on the CHEK2 AS splicing pattern, the motifs tested were not 
sufficient to abrogate SRSF1-mediated regulation of CHEK2 AS. 
 
CHEK2 splice variants have different biochemical properties   
A major point of regulation for CHEK2 proteins is a homodimerization event that 
occurs following phosphorylation of threonine 68 by ATR (Smith, Tho et al. 2010). CHEK2 
homodimers, in turn, trans-autophosphorylate at threonine 383 to become fully active 
enzymes. CHEK2Δ9 proteins lack catalytic activity due to the loss of the ATP-coordinating 
residues. This led us to hypothesize that CHEK2Δ9 might exhibit some dominant negative 
activity if it could bind, but not phosphorylate CHEK FL. To test this hypothesis, I 
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attempted to co-immunoprecipate these two variants. Reciprocal co-immunoprecipitation 
experiments revealed that CHEK FL and CHEK2Δ9 interacted in cells.  
 I next sought to measure the effect of CHEK2 phosphorylation and dimerization 
upon UV light treatment. Threonine 68 is an ATR phosphorylation site, whereas threonine 
383 is a trans auto-phosphorylation site that is modified upon dimerization. I ectopically 
expressed CHEK2 variants and immunoprecipitated each after UV damage.  Interestingly, 
I found robust phosphorylation of threonine 68 in all conditions. Threonine 383 
phosphorylation was only observed in the CHEK2 FL protein, but not the CHEK2Δ9 form 
(Figure 4.7 B). These data indicate that CHEK2Δ9 can serve as a substrate for ATR, but 
does not dimerize or trans auto phosphorylate. In support of this claim, I observed a dimer 
of CHEK2FL by gel shift upon UV damage, but this dimer was not seen with CHEK2Δ9 
proteins (Figure 4.7 C). In preliminary experiments I noted that expression of CHEK2 FL, 
but not CHEK2Δ9, increased the levels of histone H3 ser 10 phosphorylation (a marker 
of mitotic arrest) as well as a modest increase in Cyclin B levels. Furthermore, it appears 
that co-expression of CHEK2 FL and CHEK2Δ9, abrogates the effect on H3 ser 10 
phosphorylation. Together, these data support a model where CHEK2 AS can impinge 
on CHEK2 activity by producing non-functional kinases with putative dominant negative 
functions. 
 Previous studies have demonstrated that minor changes in the CHEK2 amino acid 
content due to SNPs or germline mutations can dramatically alter CHEK2 protein stability 
(Lee, Kim et al. 2001; Staalesen, Falck et al. 2004). Our preliminary data indicated that 
CHEK2∆9 was weakly expressed from an exogenous construct in 293T and HeLa cells 
as compared to CHEK2 FL (as can be observed in Figure 4.7). I sought to determine if 
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CHEK2∆9 was weakly stable as compared to CHEK2 FL. Indeed, exogenously expressed 
CHEK2∆9 levels dramatically decreased after treatment with cycloheximide, while CHEK 
FL remained largely unchanged (Figure 4.7 D). Co-treatment with cycloheximide and 
MG132 partially stabilized CHEK2∆9 expression. Because MG132 increased the 
abundance of CHEK2∆9, I next measured the ubiquitination status of this variant and 
compared it to that of CHEK2 FL or GFP. In support of these findings I found strong poly-
ubiquitiantion of CHEK2∆9 (DD and ZW). 
 
CLK1 is required for normal cell cycle progression and proliferation 
Three lines of evidence prompted us to further examine whether CLK1 activity is 
necessary for cell cycle progression:  the periodic fluctuations of CLK1 during cell division, 
the enrichment of cell cycle related genes in CLK1-regulated AS events, and the 
disruption of CENPE splicing and protein levels upon CLK1 inhibition.  To this end, I 
silenced CLK1 with RNAi, achieving protein depletion in three out of four shRNAs tested 
(Figure 4.92 A).   Loss of CLK1 led to a substantially higher fraction of cells with 4N DNA 
content in multiple cell types (i.e., HeLa, H157, A549), and this accumulation of 4N cells 
was correlated with the extent of CLK1 depletion. I also observed a significant increase 
in multi-nucleation in A549 and HeLa cells treated with CLK1 inhibitors or depleted of 
CLK1 by shRNA, consistent with defects in chromosome segregation or cytokinesis 
(Figure 4.92 B). To visualize the effect of CLK1 inhibition at the single cell level, I 
performed time-lapse high-content microscopy on live cells stably expressing a fusion 
protein of histone 2B and GFP (Figure 4.91 A). TG003-treated cells entered mitosis 
normally, as measured by nuclear envelope breakdown, but had delayed or aberrant 
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cytokinesis, typically resulting in multi-polar divisions, increased time in metaphase, 
failure to undergo chromatin de-condensation and eventual cell death (data not presented 
here).  
To determine when (in cell cycle) CLK1 activity is necessary for progression 
through mitosis, I inhibited CLK1 at different points after early S phase release using 
TG003, which was previously shown to act very rapidly in cells (<30min).  Only treatment 
before late S-phase had a significant impact on the normal progression through mitosis 
whereas cells treated 5 hours after early S phase release still underwent a round of 
normal mitotic division, although they failed to enter the next cell cycle (Figure 4.91 C). 
This result suggests that the cellular defects caused by CLK1 blockade must accumulate 
in late S-phase and G2 in order to disrupt mitosis. Consistent with this notion, mRNAs 
controlled by CLK1, like HMMR and CENPE, are maximally expressed 6 hours after 
release (Figure 4.91 D), indicating that disruption of their processing by CLK1 inhibition 
at this time is likely inconsequential to production of the corresponding protein because 
enough normally processed mRNA already exists. Finally, cells depleted of CLK1 by 
shRNA or continuously treated with TG003 or a structurally distinct CLK1 inhibitor (KHCB-
19) exhibited a near complete block of proliferation as measured by anchorage -
dependent and -independent colony formation assays (Figure 4.10 A, B and C).  
Altogether, these data demonstrate that CLK1-regulated splicing is required for normal 
mitosis and cell proliferation. 
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Discussion 
   The protein levels of CLK1 are cell cycle-dependent and are regulated via a 
negative feedback loop, in which the kinase activity of CLK1 can promote its own 
degradation through the ubiquitin-proteasome pathway. I used TG003 to selectively 
inhibit CLK1 and CLK4, however depletion of CLK1 alone was sufficient inhibit cell cycle 
progression, suggesting CLK1 is a predominant factor involved in cell cycle-control. 
Although loss of CLK1 function leads to inhibition of mitotic progression and cellular 
proliferation, it remains unclear which direct substrate(s) of CLK1 may be responsible for 
the regulation of the AS targets involved in cell cycle regulation (e.g., CENPE, CHEK2 
and CDK1). The CLK1 substrates, SRSF1 (ASF/SF2), SRSF2 (SC35) and SRSF3 
(SRP20) have previously been shown to alter cell division through diverse mechanisms 
(Loomis, Naoe et al. 2009; Fregoso, Das et al. 2013; Kurokawa, Akaike et al. 2013), but 
whether their phosphorylation is a pre-requisite for these functions remains to be tested.    
CLK1 was revealed as a key factor that controls the splicing pattern of a subset of 
cell cycle-dependent splicing events. Among the hundreds of splicing targets of CLK1, 
many are involved in cell cycle control. While I found the inhibition of CLK1 closely 
resembles the phenotype of CENPE loss (Wood, Sakowicz et al. 1997; Putkey, Cramer 
et al. 2002), it is possible that other factors also contribute the mitotic arrest by CLK1 
inhibition.  Therefore, restoration of a single mis-spliced target will most likely fail to rescue 
the phenotype of CLK1 depletion.  Additionally, I demonstrate that there may be a 
functional link between CLK1 and the DNA damage response. CHEK2 splice variants are 
regulated by CLK1 and SRSF1. Interestingly, SRSF1 has been shown to change in 
phosphorylation status upon DNA damage (Leva, Giuliano et al. 2012). One study 
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demonstrated that CLK2 over-expression can protein cells from UV-induced cell death 
(Nam, Seo et al. 2010). However, the mechanistic details of how this may occur were 
note investigated.The regulation of CHEK2 AS has been shown to be of functional 
importance in human cancer (Paronetto, Minana et al. 2011). I propose that there are 
master regulators (like CLK1) which integrate environmental cues into splicing regulatory 
networks that control ley aspects of cell division cycle (i.e. mitosis and the DNA damage 
response). 
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Figure 4.1. Cell cycle-dependent expression of CLK1 protein. (A) Immunoblot 
analysis of proteins involved in splicing regulation in synchronized HeLa cells after 
release from double thymidine block. (B) Immunoblot analysis of selected proteins in 
asynchronous cells or cells arrested at different cell cycle stages (top). Stably expressed 
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exogenous CLK1 proteins were also determined in the same set of samples (bottom). (C) 
CLK1 mRNA expression level as measured by RNA-seq experiment. CCNB1 is shown 
as a positive control. (D) Diagram depicting the alternative splicing pattern of CLK1 mRNA 
(left). The short form represents skipping of exon 4 which introduces a premature stop 
codon in the kinase domain, while long form represents the full length active isoform. 
Right panels show levels of both CLK1 variants, as measured by semi-quantitative RT-
PCR with primers that simultaneously detect both forms. Cells are shown after S phase 
release or arrested at specific stages. (E) Immunoprecipitation of Flag-CLK1 from HEKT 
cells upon MG132 treatment and subsequent detection of polyubiquitination.  The arrow 
head indicates the expected position of unmodified CLK1. 
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Figure 4.2 CLK1 protein auto-regulation during cell cycle. (A) Immunoblot of 
endogenous CLK1 (top) and exogenously expressed wild type (CLK1wt) or kinase dead 
(CLK1KD) protein (bottom) upon treatment with 10 µM TG003. (B) Protein stability of CLK1 
is affected by its activity. Cyclohexamide chase experiment was used to measure the 
stability of CLK1 in cell expressing either CLK1wt or the catalytic mutant CLK1KD. The 
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proteasome inhibitor MG132 was used as a control. (C) Co-expression of CLK1WT and 
CLK1KD at different ratios. (D) Immunoprecipitation of CLK1 proteins co-expressed with 
myc-ubiquitin. The cells were treated with 10 M TG003 and 10 M MG132 prior to 
sample collection.  A darker exposure of the input protein is also shown (bottom panel). 
(E) Immunoblotting of lysates from cells synchronized upon early S phase (double 
thymidine) release with or without TG003 treatment.  
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Figure 4.3 CLK1-regulated AS network. (A) Identification of endogenous CLK1 targets 
by RNA-seq. Experiment performed in HEKT` cells with 10 M TG003 for 18hrs.  Genes 
significantly up-regulated or down-regulated upon CLK1 inhibition (p<10-7 in Cufflink 
analysis) are shown in a scatter plot.   (B) Distribution for AS types that are regulated by 
CLK1 as identified by RNA-seq after TG003 treatment. (C) GO analysis of genes with 
TG003-regulated AS events. (D) Venn diagram showing overlap between genes with 
TG003-regulated AS and the genes with periodic AS or periodic expression, only the 
genes detected in both datasets were considered for statistic test. 
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Figure 4.4 Validation of CLK1-regulated AS network. (A, B) Semi-quantitative RT-
PCR experiments to validate splicing events predicted to change upon CLK1 inhibition. 
10 M of TG003 was added on HEKT cells and the samples were assayed at indicated 
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time points. The means PSI valules and s.d. from duplicated experiments are shown. (C) 
HMMR splicing regulation by CLK1. HEKT cells were treated with different concentrations 
of TG003 or DMSO control (lanes 1 to 3), or transfected with expression vectors of wild 
type or kinase dead CLK1 (lanes 4-6, GFP was used as control). The splicing of HMMR 
was determined by semi-quantitative RT-PCR using gene specific primers. (D) Over-
represented sequence motifs in alternative exons regulated by TG003 treatment 
(positions as diagramed). Only skipped exons were used in this statistical analysis.  
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Figure 4.5 Regulation of CENPE by CLK1 during cell cycle. (A) Normalized CENPE 
total mRNA expression during an unperturbed cell cycle (left) and diagram of CENPE 
splicing (right). (B) TG003 treatment of synchronized HeLa cultures followed by semi-
quantitative PCR assessment of CENPE isoforms (bar graph) and (C) CENPE proteins 
by immunoblot.  
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Figure 4.6 Regulation of CHEK2 by CLK1. (A) Schematic representation of CHEK2 
gene and corresponding protein below.  The alternative exon regulated by CLK1 is shown 
in gray. Threonine 383 and 384 are shown, these are auto-phosphorylation sites required 
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for full activation of CHEK2. (B) Dose-dependent change of CHEK2 AS after addition of 
TG003 as measure by semi-quantitative PCR. (C) Regulation of CHEK2 splicing by 
CLK1WT (wild type), CLK1KD (kinase dead mutant) and SRSF1. (D) Upper panel is a 
schematic of CHEK2 AS mini-gene reporter. Lower panel demonstrates regulation of 
CHEK2 mini-gene similar to the endogenous CHEK2 pre-mRNA. 
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Figure 4.7 Functional differences between CHEK2 splice variants. (A) Co-
immunoprecipitation of CHEK2 isoforms from HEK cells demonstrates and interaction 
between the CHEK2 FL and CHEK∆9. (B) Immunoprecipitation of CHEK2 isoforms from 
HEK cells treated with 25uJ/m of UV light. Lysates were immunoblotted for CHEK2 
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phosphorylation as indicated.  (C) Immunoblot of putative CHEK2 homodimers after UV 
treatment. (D) Immunoblot of HEK cells ectopically expressing each CHEK2 isoform were 
treated with CHX with and without MG132. (E) HEK cells expressing the indicated CHEK2 
variants were blotted for cell cycle markers as indicated. 
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Figure 4.8 CLK1-regulated gene and cell cycle control. (A) CLK1-targets function in 
all cell cycle stages.  The genes involved in similar cell cycle processes are clustered 
together and color-coded.  Classical cell cycle regulators are also listed below, two of 
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which are also controlled by CLK1 (marked in grey).  (B) Genes containing CLK1-
regulated AS events form a densely connected network in interaction network analysis of 
protein association. Functional interactions with high confidence threshold are shown 
(>0.7 by STRING confidence).  The highly connected nodes form clusters of genes that 
function in a common pathway (circled and labeled in red). 
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Figure 4.9. CLK1 is required for normal cell cycle progression. (A) HeLa cells 
depleted of CLK1 by 4 different shRNAs results in decrease of CLK1 protein (top). Cell 
cycle profile of cells depleted of CLK1. (B) Knockdown of CLK1 in A549 and H157 cell 
lines causes accumulation of mitotic cells.  
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Figure 4.10. CLK1 is required for normal mitosis and cytokinesis. (A) 
Immunofluorescence of A549 cells depleted of CLK1 by shRNA or cells treated with 10 
µM TG003 for 12hrs (top panel); green: tubulin, red: emerin (nuclear envelope), and blue: 
DAPI. Scale bar 10 µm. (B) Right bar graph shows the quantification of multinucleated 
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cells. Static frames from a live-cell high-content imaging movie of HeLa cells expressing 
Histone H2B-GFP and treated with TG003 (bottom panel). Time after start of the 
experiment is labeled, EP=end point (~960 min). The TG003 treated cells were shown in 
two independent fields. Both cells in the top field have apparent cell division defects, and 
the two cells with cell division defects in the bottom field are indicated by arrowheads. (C) 
Synchronized HeLa cells were treated with 20 µM TG003 at the indicated time points (0, 
5, and 10 hrs) and analyzed by propidium iodide staining followed by flow cytometry 
measurement of DNA content. Percent of 2N (upper bar graph) and 4N (lower bar graph) 
cells were quantified at each time as indicated in the treatment scheme (top). (D) Periodic 
expression of HMMR and CENPE during cell cycle. Dashed line indicates the six hour 
mark after early S phase release (sample #4, t=6 hrs), when these CLK1-targets are 
reaching peak expression.   
 
 
 
 
 
 
 
 
 
 
 
88 
 
 
 
Figure 4.11. CLK1 is required for cellular proliferation. (A)  Colony formation assay 
in HeLa cells depleted of CLK1 by shRNA, (B) or continuously treated with TG003 and 
KHCB-19 at the indicated concentrations.  (C) Anchorage-independent growth assay 
(soft agar assay) in HeLa cells after depletion of CLK1 with shRNA3. 
 
 
 
 
 
 
89 
 
 
 
 
 
V.  Mitotic trait: A computational method for inferring cell-cycle stage. 
 
Introduction 
Gene expression profiling has dramatically improved our understanding of 
biological processes (Blencowe, Ahmad et al. 2009; Koboldt, Steinberg et al. 2013). As 
noted above, transcriptome dynamics are critical for coordinating cellular events (i.e. cell 
cycle, development, differentiation and tumorigenesis). Identifying the sets of transcripts 
that are dynamically expressed and processed not only uncovers interesting biology, but 
also provides a “snap shot” of the transcriptome along a biological path.  
In malignancies, transcriptome profiling has enabled the development of statistical 
methods capable of stratifying tumors into subclasses that predict survival and/or drug 
responses (Chibon 2013). Breast cancers, for example, are incredibly heterogeneous, 
which has complicated the classification of patient tumors and stifled the development of 
treatment strategies (Peppercorn, Perou et al. 2008; Parker, Mullins et al. 2009; Prat, Ellis 
et al. 2012).  Breast cancer can be broken down by molecular subtype or “intrinsic 
subtype,” which includes luminal A, luminal B, HER2-enriched and basal-like (Prat, Ellis 
et al. 2012). Each subtype varies in its basal prognoses and response to therapy. 
Furthermore, these classifications correlate well with histo-pathological classifications as 
well as specific mutations. For example, the vast majority of basal-like and HER2-
enriched tumors are p53 null (Prat and Perou 2011).  Classification of other cancers has 
had similar success, but will not be discussed in detail here.  
 
 
90 
Importantly, the cell cycle-dependent transcriptome is severely mis-regulated in 
cancer (Johnson and Schneider-Broussard 1998; Malumbres and Barbacid 2009; Bertoli, 
Skotheim et al. 2013). Whitefield et al. also demonstrated global mis-regulation of periodic 
genes in breast cancers and lymphomas (Whitfield, Sherlock et al. 2002). The authors’ 
interpretation of these results was that rapidly proliferating tumors express the same 
genes which are present in dividing/cycling cells (periodic genes). In addition, key cell 
cycle control factors are altered or even lost altogether in cancers. However, it remains 
unclear if a tumor as a whole resembles any one particular cell cycle stage more closely 
than another. I speculate that the transcriptomes of rapidly growing tumors may more 
closely resemble M or S stages, while a slowly dividing tumor may resemble G1. This 
idea can be extended to not only tumors, but to any gene expression dataset from any 
tissue or cell type.  
The Cancer Genome Atlas (TCGA) has profiled a large number of tumor samples 
for global alterations in DNA, RNA and protein (Weinstein, Collisson et al. 2013). A 
dataset encompassing more than 12 tissues and over 3,000 samples now makes it 
possible to analyze differences and similarities across tumors. In a recent study, (Ciriello, 
Miller et al. 2013) tumors across multiple tissue types were grouped (irrespective of 
tissue) for their similarities. These data revealed two major types of tumors: those driven 
by genetic mutations (M class) and others by widespread copy number alterations (C 
class). Furthermore, a common set of pathways were activated across tumors 
irrespective of tissue type. For example, the C class contained tumors from breast, ovary 
and lung. In these tumors, some of the aberrantly activated pathways controlled different 
aspects of cell cycle progression.  Specifically, G1/S checkpoint components were 
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commonly altered. These include, p53, CDK4, CDK6, Cyclin E and Cyclin D. I 
hypothesized that a more cell cycle-focused analysis of these tumors might reveal 
additional similarities/differences across the pan-cancer landscape. 
The unbiased identification of a large set of periodically expressed transcripts 
makes it possible to examine similarities and differences between cell cycle stages. 
Beyond cell cycle stage, this dataset can also be useful in comparing any expression 
dataset to any cell cycle stage by computational approaches. I developed a statistical 
approach, termed mitotic trait, and validated this approach for predicting the cell cycle 
stage of single cells or even cell populations. Using TCGA data, I demonstrate that tumors 
can be re-classified based on what cell cycle stage they “look” like. I show a high degree 
of heterogeneity in mitotic trait across tumors that can be in part explained by genetic 
alterations of key cell cycle factors (i.e. p53). Interestingly, tumors can be clustered 
together by mitotic trait and their similarities are independent from tumor tissue of origin. 
 
Results 
Mitotic trait of cells based on transcriptome profile  
Using a pairwise correlation analysis to compare every pair of the 14 samples, I 
found a high degree of positive correlation between samples in the same stages and 
robust negative correlation between different stages (Figure 5.1 A). These cell cycle 
stage-dependent correlations can only be observed when periodic transcripts are used 
for this analysis.  A control set of 1,000 arbitrarily selected transcripts or all detected 
transcripts showed no significant correlation between samples representing the same cell 
cycle stage (Figure 5.1 B and C). This preliminary analysis suggests that any gene 
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expression dataset can be compared to the 14 cell cycle samples to infer cell cycle stage 
by correlation analysis. Our approach is very similar to gene expression signatures that 
have been widely used to classify tumor types. In this case, however, our data has 
generated gene expression signature that predicts cell cycle stage. Importantly, these 
methods are robust yet computationally light.  
 
Mitotic trait of single cells from the human embryo 
 I obtained RNA sequencing data from single cells of the developing embryo (89 
individual cells) (Yan, Yang et al. 2013). These data are useful because I expect each 
individual cell to resemble only one cell cycle stage, as one cell can only reside in a single 
point along cell cycle.  I found that cells in early development (from zygote to morula) 
have an expression pattern similar to cells in G2 and M phase (samples 4, 5 in first cycle 
and 10, 11 in second cycle) (Figure 5.2). Interestingly, the periodic genes in all single 
cells at the same developmental stage have nearly identical expression patterns.  These 
findings are consistent with the fact that early embryos undergo rapid sequential mitosis 
and must be poised with a transcriptome that is apt for these molecular events (Clift and 
Schuh 2013). Additionally, early embryonic cells express almost exclusively maternal 
mRNAs that are derived from the oocyte – as daughter cells are transcriptionally inactive 
until 4-cell divisions (Braude, Bolton et al. 1988). Consistently, single oocyte 
transcriptomes displayed a G2 and M mitotic trait (Figure 5.2) and oocytes to 4-cell stage 
are nearly identical in terms of mitotic trait. These data indicate that the vast majority of 
cell cycle control in early embryogenesis is governed by maternal RNAs.  
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Mitotic trait of human breast cancers 
I expanded our examination of mitotic trait using extensive RNA-seq data from The 
Cancer Genome Atlas  (TCGA) project (Weinstein, Collisson et al. 2013).  I focused on 
breast cancers and their normal controls, which represent a heterogeneous disease 
containing well-annotated information on molecular subtypes and common mutations 
(Parker, Mullins et al. 2009). Expression correlation was carried out to compute the mitotic 
trait of breast samples and correlation to only four representative cell cycle stages was 
plotted for simplicity (Figure 5.3).  Strikingly, all normal tissues correlate strongly with G1 
phase while tumor samples have a diverse array of mitotic traits, consistent with the high 
degree of tumor-to-tumor variability. To further study such variability, I grouped the breast 
samples according to the molecular subtypes (Parker, Mullins et al. 2009), and found that 
different tumor types correlate with characteristic mitotic traits ((Figure 5.3). Interestingly, 
the luminal A subtype is generally G1-like, consistent with the fact that most of these 
tumors have wild type TP53 (but mutated PIK3CA) while loss of TP53 in other subtypes 
results in an S, G2, or M trait. This may also help explain why the relapse-free survival 
for the luminal A subtype is the best among all subtypes. In addition, the published 
molecular subtype according to PAM50 has classified a small number of tumors as 
normal (Parker, Mullins et al. 2009). Amazingly, these “normal-like” tumors do not 
resemble normal tissue in mitotic trait analysis (Figure 2B, shown by asterisk), suggesting 
our classification can extract reliable differences between normal and tumor cells.   
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Pan-cancer analysis by mitotic trait 
 I next applied mitotic trait analysis to 3,934 samples from 12 different tissue types 
(Figure 5.4 A). I noted that nearly all normal tissues have a mitotic trait that represents 
G1 phase. The only exception was head and neck cancer normal tissue which was a 
mixed in mitotic trait analysis.  It is unclear to us why this normal tissue is an outlier. The 
G1 mitotic trait of normal tissues reinforces the notion that adult tissues are fairly non-
proliferative and I were surprised that this relatively simple computation approach reflects 
that so strongly. When tumors were examined, heterogeneity was observed. Not all tumor 
types were heterogeneous; kidney and bladder tumors were very similar across all 
samples. In fact, kidney tumors appear to be no different from normal kidney tissue in 
their mitotic trait. I hierarchically clustered tumors based on mitotic trait and noted that 
tumors tend to cluster with each other irrespective of tissue of origin (Figure 5.4 B). 
Together these data argue that mitotic trait can predict a proliferative state across many 
normal and aberrant tissue types.  
 
Discussion 
It is worth noting that mitotic trait reflects a relative correlation to a cell cycle stage 
rather than a direct prediction of cell cycle stage, therefore this analysis should result in 
more reliable correlations when using larger set of samples in the analysis. Our result 
from the developing embryo showed that early embryos strongly resemble G2 and M 
phase while late blastocysts resemble G1 and S phase cells (Figure 2B). It is well known 
that the mature oocyte is arrested at metaphase II of the meiotic cycle awaiting fertilization, 
in which transcription is also suspended until the oocyte is fertilized and undergoes 
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several rounds of subsequent mitotic division (Clift and Schuh 2013). In human embryos, 
it is believed that transcription reinitiates between 4 to 8 cell stages. 
Our data suggested that the G2-M-like expression pattern of periodic transcripts 
remains nearly unchanged from oocyte to 4-cell embryo. Consistently the mitotic trait of 
developing embryo starts to change at the 4-cell phase and eventually becomes G1-S-
like at the late blastocyst stages. I were also able to infer the mitotic trait of adult tissues, 
which are generally composed of many cell types. Different human tissues preferentially 
correlate with specific cycle stages even though the measured expression data is an 
average of many different cells (Figure S2C). Some tissues, like brain or heart, do not 
resemble any cell cycle stage. A possible explanation is that these tissues contain too 
diverse of a cellular composition for this analysis. Alternatively, the gene expression 
profile in brain or heart may be too different from HeLa cells such that a mitotic trait cannot 
be reliably derived.  
In breast cancer, I found that every normal breast, much like our initial 16 tissue 
analysis, resembles the G1 stage. However breast tumors have very diverse mitotic trait: 
some tumor samples resemble G1 phase, while most other cells resemble S, G2 or M 
phase.  Our result reiterates the high transcriptome variability among cancers and 
suggests, as expected, that cancers often have deregulated cell cycle. Importantly, this 
analysis independently recapitulates the function of TP53, specifically in control of G1 
checkpoint.  
Our application of mitotic trait analysis to over 3,000 tumors revealed some key 
differences in the inferred cell cycle stage across tissue types and corroborates the 
heterogeneity across some tumors arising from the same tissue. For example, kidney 
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tumors almost exclusive correlate with G1 phase, while bladder tumors correlate with S 
and G2 phases. Most other tumor types represented a mixture. One of the most 
interesting finds from this analysis is the clustering of tumor irrespective of tissue of origin. 
That is, in terms of cell cycle stage, a kidney tumor can be more similar to a breast tumor 
than it is to another kidney tumor. Given that our gene signature includes over 1,000 
genes, one would expect tissues to cluster with each other, as would likely occur if I had 
arbitrarily selected a random set of genes (Figure 5.1 B and C). However, this is not the 
case. Instead, it appears that these 1,000 genes indeed reflect a cell cycle state. In the 
future, it will be important to investigate the mutational status of all tumors. It may be that 
mutation of key cell cycle regulators (as was observed with p53) will dictate mitotic trait. 
In addition, I speculate that mitotic trait may uncover vulnerabilities in cell cycle that might 
be useful in for guiding therapeutic interventions.  
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Figure 5.1. Pairwise sample correlations (A) Spearman’s rank correlation with 1,182 
periodic transcripts, (B) with 1,000 arbitrarily selected non-periodic genes or (B) all 
transcripts detected in Hela cells.  
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Figure 5.2. Mitotic trait of single cells from the human embryo. (A) Pairwise 
Spearman’s rank correlation analysis on all possible pairs within the 14 synchronous 
samples (left) and between synchronous cells and single cells in developing embryos 
(Right).  The normalized expression levels of all periodic genes were calculated using 
RNA-seq data from synchronous cells or the single embryonic cells to compute the 
Spearman’s rank correlation between each sample pair. (B) The comparison of periodic 
gene expression between human breast tumors and the synchronous cells.   
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Figure 5.3. Mitotic trait analysis of breast tumors according to molecular subtype.  
(A) Pairwise Spearman’s rank correlation between cancers and four representative cell 
cycle stages were plotted (synchronous samples #7, 9, 11, and 5, representing cell cycle 
phases G1, S, G2, M respectively). Breast tumors were grouped together according to 
PAM50 molecular subtype classification. The most common genetic mutations in each 
tumor sample are also indicated in black. 
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Figure 5.4. Pancancer mitotic trait analysis of 3934 normal and tumor samples. (A) 
Pairwise Spearman’s rank correlation between cancers and four representative cell cycle 
stages were plotted (synchronous samples #7, 9, 11, and 5,representing cell cycle 
phases G1, S, G2, M respectively). Tissue type is represented by color bar on left.  
Tumors were grouped together according tissue of origin and by normal (black bar) vs. 
tumor (red bar) on right. BLCA: Bladder urothelial carcinoma, BRCA:Breast invasive 
carcinoma, COAD: Colorectal adenocarcinoma, GBM: Glioblastoma multiformae, HNSC: 
Head and neck squamous cell carcinoma, KIRC: Kidney renal clear cell carcinoma, 
 1               -0.9 
Spearman’s rank 
correlation coefficient 
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LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous 
cell carcinoma, OV:  Ovarian serous cystadenocarcinoma, READ: Rectum 
adenocarcinoma, UCEC: Uterine corpus endometrioid carcinoma. (B) Hierarchical 
classification of all tumors reveals clustering independent of tissue type. 
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VI. Concluding remarks 
 
Here I report the profiling of the transcriptome at single nucleotide resolution 
through two continuous mitotic cycles with a comprehensive analysis. I identified more 
than 1,000 cell cycle-dependent transcripts, including 40 long non-coding RNA that are 
periodically expressed during the cell cycle.  Furthermore, I found widespread 
coordination of periodic alternative splicing with cell division, a new observation that 
presents a novel regulatory mode for cell cycle progression.   Mechanistically, I 
determined how cell cycle-dependent alternative splicing is regulated by a protein kinase 
CLK1.  In addition, inhibition of CLK1 led to inhibition of mitotic progression and cellular 
proliferation, suggesting that the temporal regulation of splicing during cell cycle is critical 
for progression through the cell division cycle.  Our work is summarized in the model 
below (Figure 6.1). In addition, I developed mitotic trait, a computational method for 
inferring cell cycle stage from gene expression data. Mitotic trait analysis of normal and 
tumor tissues demonstrates the robustness of this approach in inferring cell cycle 
differences across these samples. I also noted loss of G1 state in p53-null tumors, again 
suggesting the power of this tool in corroborating previously known information.  
Still many questions remain: Why is the cell cycle-dependent transcriptome so cell 
type-dependent? This question emanates from the very modest overlap of periodic genes 
across multiple cell lines (only 67 of close to 3,000 identified). It would be of great value 
to the cell cycle field if a single laboratory could measure the periodic transcriptome 
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across a panel of cell lines utilizing the same techniques. This approach should eliminate 
the experimental differences across laboratories. This is especially interesting when it 
comes to the differences between normal and cancer cell lines, as tumor cells have poorly 
regulated cell cycle.   Furthermore, if inherent cell line (or tissue)-dependent differences 
are observed, the underlying regulatory factors accounting for these changes could be 
studied.  
Is periodic AS a general feature of cell cycle regulation in other cell types and 
organisms? How frequently does periodic AS alter protein function? Alternative splicing 
is undoubtedly a critical component of gene expression and is highly tissue-specific. My 
work opens a new area of study during cell cycle. It will be important to see how general 
periodic splicing is, and if the regulated genes are conserved from cell-to-cell.  The overall 
consequence of periodic splicing on protein sequence and function can be very difficult 
to assess, however I do know that at least a subset of the identified periodic events lead 
to loss of protein production (greater than 30%). A future direction is to annotate how 
subtle changes in the amino acid composition of polypeptides as a consequence of AS 
alters their function.  
What are the other regulators of periodic AS besides CLK1? I demonstrated that 
hundreds of RNA-binding protein show periodic fluctuations at the RNA level, however if 
these changes are also observed at the protein level is still unclear. The presence of cis 
sequence motifs in periodic exons leads me to hypothesize that there is a complex 
regulatory network that controls periodic AS. In the future it will be beneficial to determine 
how the cell coordinates this network to achieve a faithful cell division. 
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CLK1 emerged as an important molecule that controls cell cycle via AS regulation, 
a function that had not yet been assigned to this protein. How is CLK1 protein degraded 
during cell cycle (E3 ligase)? I can clearly show that an auto-inhibitory loop exists to 
control CLK1 periodic expression, but the rest of the molecular machinery that controls 
CLK1 is still unknown. In preliminary experiments, I identified the Skp2-Cul1-F-box 
complex as a putative E3 ligase. This complex seems like an ideal candidate because of 
the timing CLK1 protein turnover and the pre-requisite for phosphorylation.  Can CLK1 
substrates whose phosphorylation depends on cell cycle stage be identified? Using mass 
spectrometry I identified a set of proteins whose phosphorylation changed upon treatment 
with TG003, although most these proteins are indeed RNA-binding factors these results 
remain preliminary and have not yet been validated. From a cancer and therapeutic 
perspective, are CLK1 inhibitors effective in blocking tumor cell proliferation in animal 
models and, if so, does the mechanism involve splicing regulation and cell cycle?  
 Together this work delineates a new regulatory pathway involved in cell cycle 
control. This work opens a new area of study in cell cycle regulation. To the best of our 
knowledge this represents the first demonstration that alternative splicing is cell cycle-
dependent.  
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Figure 6.1. Model. Periodic expression of lncRNAs and periodic alternative splicing 
occurs during cell cycle. These mechanisms complement the classical regulators of cell 
cycle progression shown in gray. CLK1 was shown to auto-regulate its own protein levels 
during cell cycle via the ubiquitin-proteasome pathway. I propose that CLK1 differentially 
phosphorylates SR proteins during cell cycle to control a splicing network of genes with 
cell cycle functions, many of which are periodically spliced. Disruption of CLK1 activity 
leads to cell pronounced cycle defects. 
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